Abstract
Parkinson’s disease (PD) is one of the progressive neurological diseases which affect around 10 million population worldwide. The clinical manifestation of motor symptoms in PD patients appears later when most dopaminergic neurons have degenerated. Thus, for better management of PD, the development of accurate biomarkers for the early prognosis of PD is imperative. The present work will discuss the potential biomarkers from various attributes covering biochemical, microRNA, and neuroimaging aspects (α-synuclein, DJ-1, UCH-L1, β-glucocerebrosidase, BDNF, etc.) for diagnosis, recent development in PD management, and major limitations with current and conventional anti-Parkinson therapy. This manuscript summarizes potential biomarkers and therapeutic targets, based on available preclinical and clinical evidence, for better management of PD.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
No new data were created or analysed in this study. Data sharing does not apply to this article.
References
Aarsland D, Batzu L, Halliday GM, Geurtsen GJ, Ballard C, Ray Chaudhuri K, Weintraub D (2021) Parkinson disease-associated cognitive impairment. Nat Rev Dis Primers 7(1):47. https://doi.org/10.1038/s41572-021-00280-3. Erratum in: Nat Rev Dis Primers. 2021 Jul 13;7(1):53.
Ahmad J, Haider N, Khan MA, Md S, Alhakamy NA, Ghoneim MM, Alshehri S, Sarim Imam S, Ahmad MZ, Mishra A (2022) Novel therapeutic interventions for combating Parkinson’s disease and prospects of Nose-to-Brain drug delivery. Biochem Pharmacol. 195:114849. https://doi.org/10.1016/j.bcp.2021.114849
Alarcón-Arís D, Recasens A, Galofré M, Carballo-Carbajal I, Zacchi N, Ruiz-Bronchal E, Pavia-Collado R, Chica R, Ferrés-Coy A, Santos M et al (2018) Selective α-Synuclein Knockdown in Monoamine Neurons by Intranasal Oligonucleotide Delivery: Potential Therapy for Parkinson’s Disease. Mol Ther 26:550–567
Albi E, Cataldi S, Codini M, Mariucci G, Lazzarini A, Ceccarini MR, Ferri I, Laurenti ME, Arcuri C, Patria F et al (2019) Neutral sphingomyelinase increases and delocalizes in the absence of Toll-Like Receptor 4: A new insight for MPTP neurotoxicity. Prostaglandins Other Lipid Mediat 142:46–52
Alcalay RN, Mallet V, Vanderperre B, Tavassoly O, Dauvilliers Y, Wu RYJ, Ruskey JA, Leblond CS, Ambalavanan A, Laurent SB et al (2019) SMPD1 mutations, activity, and α-synuclein accumulation in Parkinson’s disease. Mov Disord 34:526–535
Alecu I, Bennett SAL (2019) Dysregulated Lipid Metabolism and Its Role in α-Synucleinopathy in Parkinson’s Disease. Front Neurosci 13:328
Andrews LP, Marciscano AE, Drake CG, Vignali DAA (2017) LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev 276:80–96
Angelopoulou E, Paudel YN, Villa C, Shaikh MF, Piperi C (2020) Lymphocyte-Activation Gene 3 (LAG3) Protein as a Possible Therapeutic Target for Parkinson’s Disease: Molecular Mechanisms Connecting Neuroinflammation to α-Synuclein Spreading Pathology. Biology 9:86
Angelopoulou E, Paudel YN, Piperi C, Mishra A (2021) Neuroprotective potential of cinnamon and its metabolites in Parkinson's disease: Mechanistic insights, limitations, and novel therapeutic opportunities. J Biochem Mol Toxicol. e22720. https://doi.org/10.1002/jbt.22720
Anis E, Zafeer MF, Firdaus F, Islam SN, Anees Khan A, Ali A, Hossain MM (2020) Ferulic acid reinstates mitochondrial dynamics through PGC1α expression modulation in 6-hydroxydopamine lesioned rats. Phytother Res 34:214–226
Aoyama S, Kase H, Borrelli E (2000) Rescue of locomotor impairment in dopamine D2 receptor-deficient mice by an adenosine A2A receptor antagonist. J Neurosci 20(15):5848–5852. https://doi.org/10.1523/JNEUROSCI.20-15-05848.2000
Ascherio A, Chen H (2003) Caffeinated clues from epidemiology of Parkinson’s disease. Neurology 61(11 Suppl 6):S51–S54. https://doi.org/10.1212/01.wnl.0000095213.86899.21
Asmarian N, Ruzitalab A, Erjaee G, Farahi MH, Asmarian SM (2021) Parkinson’s Disease Rating Scale Using Synchronization Analysis of Gait Dynamics. Biomed Res Int 25(2021):5651519. https://doi.org/10.1155/2021/5651519
Atashrazm F, Dzamko N (2016) LRRK2 inhibitors and their potential in the treatment of Parkinson’s disease: Current perspectives. Clin Pharmacol Adv Appl 8:177–189
Atashrazm F, Hammond D, Perera G, Dobson-Stone C, Mueller N, Pickford R, Kim WS, Kwok JB, Lewis SJG, Halliday GM, Dzamko N (2018) Reduced glucocerebrosidase activity in monocytes from patients with Parkinson’s disease. Sci Rep 8(1):15446. https://doi.org/10.1038/s41598-018-33921-x
Athauda D, Foltynie T (2016) The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson’s disease: Mechanisms of action. Drug Discov Today 21:802–818
Athauda D, Maclagan K, Skene S, Bajwa-Joseph M, Letchford D, Chowdhury K, Hibbert S, Budnik N, Zampedri L, Dickson J et al (2017) Exenatide once weekly versus placebo in Parkinson’s disease: A randomised, double-blind, placebo-controlled trial. Lancet 390:1664–1675
Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Ell P, Soderlund T, Whitton P, Wyse R, Isaacs T, Lees A et al (2013) Exenatide and the treatment of patients with Parkinson’s disease. J Clin Investig 123:2730–2736
Balestrino R, Schapira AHV (2020) Parkinson disease. Eur J Neurol 27:27–42. https://doi.org/10.1111/ene.14108
Ballard CG, Kreitzman DL, Isaacson S, Liu IY, Norton JC, Demos G, Fernandez HH, Ilic TV, Azulay JP, Ferreira JJ, Abler V, Stankovic S, 015 Study Group (2020) Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson’s disease psychosis. Parkinsonism Relat Disord. 77:100–106. https://doi.org/10.1016/j.parkreldis.2020.06.026
Bandopadhyay R, Mishra N, Rana R, Kaur G, Ghoneim MM, Alshehri S, Mustafa G, Ahmad J, Alhakamy NA, Mishra A (2022) Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson’s Disease: A Perspective Through Preclinical and Clinical Evidence. Front Pharmacol. 13:805388. https://doi.org/10.3389/fphar.2022.805388
Baptista MAS, Merchant K, Barrett T, Bhargava S, Bryce DK, Ellis JM, Estrada AA, Fell MJ, Fiske BK, Fuji RN et al (2020) LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits. Sci Transl Med 12:0820
Bara-Jimenez W, Sherzai A, Dimitrova T, Favit A, Bibbiani F, Gillespie M, Morris MJ, Mouradian MM, Chase TN (2003) Adenosine A(2A) receptor antagonist treatment of Parkinson’s disease. Neurology 61(3):293–296. https://doi.org/10.1212/01.wnl.0000073136.00548.d4
Barker RA (2019) TRANSEURO consortium. Designing stem-cell-based dopamine cell replacement trials for Parkinson’s disease. Nat Med. 25(7):1045–1053. https://doi.org/10.1038/s41591-019-0507-2
Bar-On P, Crews L, Koob AO, Mizuno H, Adame A, Spencer B, Masliah E (2008) Statins reduce neuronal α-synuclein aggregation in in vitro models of Parkinson’s disease. J Neurochem 105:1656–1667
Basak I, Patil KS, Alves G, Larsen JP, Møller SG (2016) microRNAs as neuroregulators, biomarkers and therapeutic agents in neurodegenerative diseases. Cell Mol Life Sci 73(4):811–827. https://doi.org/10.1007/s00018-015-2093-x
Berger AA, Winnick A, Welschmeyer A, Kaneb A, Berardino K, Cornett EM, Kaye AD, Viswanath O, Urits I (2020) Istradefylline to Treat Patients with Parkinson’s Disease Experiencing “Off” Episodes: A Comprehensive Review. Neurol Int 12(3):109–129. https://doi.org/10.3390/neurolint12030017
Bergman J, Lerner V (2002) Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson’s disease. Clin Neuropharmacol. 25(2):107–10. https://doi.org/10.1097/00002826-200203000-00009
Bezard E, Gerlach I, Moratalla R, Gross CE, Jork R (2006) 5-HT1A receptor agonist-mediated protection from MPTP toxicity in mouse and macaque models of Parkinson’s disease. Neurobiol Dis 23(1):77–86. https://doi.org/10.1016/j.nbd.2006.02.003
Bibbiani F, Oh JD, Chase TN (2001) Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 57(10):1829–1834. https://doi.org/10.1212/wnl.57.10.1829
Bibbiani F, Oh JD, Petzer JP, Castagnoli N Jr, Chen JF, Schwarzschild MA, Chase TN (2003) A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson’s disease. Exp Neurol 184(1):285–294. https://doi.org/10.1016/s0014-4886(03)00250-4
Bienias K, Fiedorowicz A, Sadowska A, Prokopiuk S, Car H (2016) Regulation of sphingomyelin metabolism. Pharmacol Rep 68:570–581
Bloem BR, Okun MS, Klein C (2021) Parkinson’s disease. Lancet 397(10291):2284–2303. https://doi.org/10.1016/S0140-6736(21)00218-X
Bohnen NI, Koeppe RA, Minoshima S, Giordani B, Albin RL, Frey KA, Kuhl DE (2011) Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study. J Nucl Med. 52(6):848–55. https://doi.org/10.2967/jnumed.111.089946
Bordia T, Campos C, Huang L, Quik M (2008) Continuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson’s disease. J Pharmacol Exp Ther 327(1):239–247. https://doi.org/10.1124/jpet.108.140897
Bouwmans AE, Vlaar AM, Mess WH, Kessels A, Weber WE (2013) Specificity and sensitivity of transcranial sonography of the substantia nigra in the diagnosis of Parkinson’s disease: prospective cohort study in 196 patients. BMJ Open. 3(4):e002613. https://doi.org/10.1136/bmjopen-2013-002613
Bové J, Martinez-Vicente M, Vila M (2011) Fighting neurodegeneration with rapamycin: Mechanistic insights. Nat Rev Neurosci 12:437–452
Briggs CE, Wang Y, Kong B, Woo TU, Iyer LK, Sonntag KC (2015) Midbrain dopamine neurons in Parkinson’s disease exhibit a dysregulated miRNA and target-gene network. Brain Res. 1618:111–21. https://doi.org/10.1016/j.brainres.2015.05.021
Brown PJ, Smith-Oliver TA, Charifson PS, Tomkinson N, Fivush AM, Sternbach DD, Wade LE, Orband-Miller L, Parks DJ, Blanchard SG et al (1997) Identification of peroxisome proliferator-activated receptor ligands from a biased chemical library. Chem Biol 4:909–918
Brys M, Fanning L, Hung S, Ellenbogen A, Penner N, Yang M, Welch M, Koenig E, David E, Fox T, Makh S, Aldred J, Goodman I, Pepinsky B, Liu Y, Graham D, Weihofen A, Cedarbaum JM (2019) Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054. Mov Disord. 34(8):1154–1163. https://doi.org/10.1002/mds.27738
Buddhala C, Campbell MC, Perlmutter JS, Kotzbauer PT (2015) Correlation between decreased CSF α-synuclein and Aβ1-42 in Parkinson disease. Neurobiol Aging. 36(1):476–84. https://doi.org/10.1016/j.neurobiolaging.2014.07.043
Buongiorno M, Antonelli F, Compta Y, Fernandez Y, Pavia J, Lomeña F, Ríos J, Ramírez I, García JR, Soler M, Cámara A, Fernández M, Basora M, Salazar F, Sanchez-Etayo G, Valldeoriola F, Barrio JR, Marti MJ (2017) Cross-Sectional and Longitudinal Cognitive Correlates of FDDNP PET and CSF Amyloid-β and Tau in Parkinson’s Disease1. J Alzheimers Dis 55(3):1261–1272. https://doi.org/10.3233/JAD-160698
Burciu RG, Ofori E, Archer DB, Wu SS, Pasternak O, McFarland NR, Okun MS, Vaillancourt DE (2017) Progression marker of Parkinson’s disease: a 4-year multi-site imaging study. Brain 140(8):2183–2192. https://doi.org/10.1093/brain/awx146
Caggiu E, Paulus K, Mameli G, Arru G, Sechi GP, Sechi LA (2018) Differential expression of miRNA 155 and miRNA 146a in Parkinson’s disease patients. eNeurologicalSci 13:1–4. https://doi.org/10.1016/j.ensci.2018.09.002
Calabrese V, Di Maio A, Marino G, Cardinale A, Natale G, De Rosa A, Campanelli F, Mancini M, Napolitano F, Avallone L et al (2020) Rapamycin, by Inhibiting mTORC1 Signaling, Prevents the Loss of Striatal Bidirectional Synaptic Plasticity in a Rat Model of L-DOPA-Induced Dyskinesia. Front Aging Neurosci 12:230
Calon F, Goulet M, Blanchet PJ, Martel JC, Piercey MF, Bédard PJ, Di Paolo T (1995) Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA receptors in the striatopallidal complex. Brain Res 680(1–2):43–52. https://doi.org/10.1016/0006-8993(95)00229-j
Calon F, Morissette M, Rajput AH, Hornykiewicz O, Bédard PJ, Di Paolo T (2003) Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications. Mov Disord 18(3):241–253. https://doi.org/10.1002/mds.10343
Carmine Belin A, Westerlund M, Bergman O, Nissbrandt H, Lind C, Sydow O, Galter D (2007) S18Y in ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) associated with decreased risk of Parkinson’s disease in Sweden. Parkinsonism Relat Disord 13(5):295–298. https://doi.org/10.1016/j.parkreldis.2006.12.002
Carrasco E, Casper D, Werner P (2005) Dopaminergic neurotoxicity by 6-OHDA and MPP+ : Differential requirement for neuronal cyclooxygenase activity. J Neurosci Res 81:121–131
Carroll CB, Webb D, Stevens KN, Vickery J, Eyre V, Ball S, Wyse R, Webber M, Foggo A, Zajicek J et al (2019) Simvastatin as a neuroprotective treatment for Parkinson’s disease (PD STAT): Protocol for a double-blind, randomised, placebo-controlled futility study. BMJ Open 9:e029740
Carta M, Carlsson T, Kirik D, Björklund A (2007) Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 130(Pt 7):1819–1833. https://doi.org/10.1093/brain/awm082
Cataldi S, Arcuri C, Hunot S, Légeron F-P, Mecca C, Garcia-Gil M, Lazzarini A, Codini M, Beccari T, Tasegian A et al (2017) Neutral Sphingomyelinase Behaviour in Hippocampus Neuroinflammation of MPTP-Induced Mouse Model of Parkinson’s Disease and in Embryonic Hippocampal Cells. Mediat Inflamm 2017:1–8
Chan H, Paur H, Vernon AC, Zabarsky V, Datla KP, Croucher MJ, Dexter DT (2010) Neuroprotection and Functional Recovery Associated with Decreased Microglial Activation Following Selective Activation of mGluR2/3 Receptors in a Rodent Model of Parkinson’s Disease. Parkinsons Dis 2010:190450. https://doi.org/10.4061/2010/190450
Charvin D, Medori R, Hauser RA, Rascol O (2018) Therapeutic strategies for Parkinson disease: Beyond dopaminergic drugs. Nat Rev Drug Discov 17:804–822
Chatterjee D, Bhatt M, Butler D, De Genst E, Dobson CM, Messer A, Kordower JH (2018) Proteasome-targeted nanobodies alleviate pathology and functional decline in an α-synuclein-based Parkinson’s disease model. NPJ Parkinsons Dis 4:25
Chaturvedi RK, Beal MF (2008) PPAR: A therapeutic target in Parkinson’s disease. J Neurochem 106:506–518
Chau E, Kim H, Shin J, Martinez A, Kim JR (2021) Inhibition of alpha-synuclein aggregation by AM17, a synthetic resveratrol derivative. Biochem Biophys Res Commun. 574:85–90. https://doi.org/10.1016/j.bbrc.2021.08.049
Chen Y, Xu R (2016) Phenome-based gene discovery provides information about Parkinson’s disease drug targets. BMC Genom 17:493
Chen JF, Xu K, Petzer JP, Staal R, Xu YH, Beilstein M, Sonsalla PK, Castagnoli K, Castagnoli N Jr, Schwarzschild MA (2001) Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson’s disease. J Neurosci. 21(10):RC143. https://doi.org/10.1523/JNEUROSCI.21-10-j0001.2001
Chen L, Xue L, Zheng J, Tian X, Zhang Y, Tong Q (2019) PPARß/δ agonist alleviates NLRP3 inflammasome-mediated neuroinflammation in the MPTP mouse model of Parkinson’s disease. Behav Brain Res 1(356):483–489. https://doi.org/10.1016/j.bbr.2018.06.005
Chen TJ, Feng Y, Liu T, Wu TT, Chen YJ, Li X, Li Q, Wu YC (2020) Fisetin Regulates Gut Microbiota and Exerts Neuroprotective Effect on Mouse Model of Parkinson’s Disease. Front Neurosci 14:549037. https://doi.org/10.3389/fnins.2020.549037
Cheng C-F, Ku H-C, Lin H (2018) PGC-1α as a Pivotal Factor in Lipid and Metabolic Regulation. Int J Mol Sci 19:3447
Chen-Plotkin AS, Hu WT, Siderowf A, Weintraub D, Goldmann Gross R, Hurtig HI, Xie SX, Arnold SE, Grossman M, Clark CM, Shaw LM, McCluskey L, Elman L, Van Deerlin VM, Lee VM, Soares H, Trojanowski JQ (2011) Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Ann Neurol 69(4):655–63. https://doi.org/10.1002/ana.22271
Cilloni D, Saglio G (2012) Molecular pathways: BCR-ABL. Clin Cancer Res 18(4):930–937. https://doi.org/10.1158/1078-0432.CCR-10-1613
Clark J, Reddy S, Zheng K, Betensky RA, Simon DK (2011) Association of PGC-1alphapolymorphisms with age of onset and risk of Parkinson’s disease. BMC Med Genet 12:69
Clark LN, Chan R, Cheng R, Liu X, Park N, Parmalee N, Kisselev S, Cortes E, Torres PA, Pastores GM et al (2015) Gene-Wise Association of Variants in Four Lysosomal Storage Disorder Genes in Neuropathologically Confirmed Lewy Body Disease. PLoS ONE 10:e0125204
Coccurello R, Breysse N, Amalric M (2004) Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats. Neuropsychopharmacology 29(8):1451–1461. https://doi.org/10.1038/sj.npp.1300444
Cole TA, Zhao H, Collier TJ, Sandoval I, Sortwell CE, Steece-Collier K, Daley BF, Booms A, Lipton J, Welch M, Berman M, Jandreski L, Graham D, Weihofen A, Celano S, Schulz E, Cole-Strauss A, Luna E, Quach D, Mohan A, Bennett CF, Swayze EE, Kordasiewicz HB, Luk KC, Paumier KL (2021) α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease. JCI Insight 6(5):e135633. https://doi.org/10.1172/jci.insight.135633
Coppedè F (2012) Genetics and epigenetics of Parkinson’s disease. ScientificWorldJournal. 2012:489830. https://doi.org/10.1100/2012/489830
Costa G, Abin-Carriquiry JA, Dajas F (2001) Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra. Brain Res 888(2):336–342. https://doi.org/10.1016/s0006-8993(00)03087-0
Costa CM, Oliveira GL, Fonseca ACS, Lana RC, Polese JC, Pernambuco AP (2019) Levels of cortisol and neurotrophic factor brain-derived in Parkinson’s disease. Neurosci Lett. 708:134359. https://doi.org/10.1016/j.neulet.2019.134359
Cova I, Priori A (2018) Diagnostic biomarkers for Parkinson’s disease at a glance: where are we? J Neural Transm (vienna) 125(10):1417–1432. https://doi.org/10.1007/s00702-018-1910-4
Cowell RM, Blake KR, Inoue T, Russell JW (2008) Regulation of PGC-1α and PGC-1α-responsive genes with forskolin-induced Schwann cell differentiation. Neurosci Lett 439:269–274
Cui S, Du J, Liu S, Meng J, Lin Y, Li G, He Y, Zhang P, Chen S, Wang G (2018) Serum soluble lymphocyte activation gene-3 as a diagnostic biomarker in Parkinson’s disease: A pilot multicenter study. Mov Disord 34:138–141
Cuzzocrea S, Bruscoli S, Mazzon E, Crisafulli C, Donato V, Di Paola R, Velardi E, Esposito E, Nocentini G, Riccardi C (2007) Peroxisome Proliferator-Activated Receptor-α Contributes to the Anti-Inflammatory Activity of Glucocorticoids. Mol Pharmacol 73:323–337
Dagan E, Schlesinger I, Ayoub M, Mory A, Nassar M, Kurolap A, Peretz-Aharon J, Gershoni-Baruch R (2015) The contribution of Niemann-Pick SMPD1 mutations to Parkinson disease in Ashkenazi Jews. Park Relat Disord 21:1067–1071
Damri O, Shemesh N, Agam G (2020) Is There Justification to Treat Neurodegenerative Disorders by Repurposing Drugs? The Case of Alzheimer’s Disease, Lithium, and Autophagy. Int J Mol Sci 22:189
De Deurwaerdère P, Di Giovanni G, Millan MJ (2017) Expanding the repertoire of L-DOPA’s actions: A comprehensive review of its functional neurochemistry. Prog Neurobiol 151:57–100. https://doi.org/10.1016/j.pneurobio.2016.07.002
De Lella Ezcurra AL, Chertoff M, Ferrari C, Graciarena M, Pitossi F (2010) Chronic expression of low levels of tumor necrosis factor-α in the substantia nigra elicits progressive neurodegeneration, delayed motor symptoms and microglia/macrophage activation. Neurobiol Dis 37(3):630–640. https://doi.org/10.1016/j.nbd.2009.11.018
de Faria SM, de Morais FD, Tumas V, Castro PC, Ponti MA, Hallak JE, Zuardi AW, Crippa JAS, Chagas MHN (2020) Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson’s disease. J Psychopharmacol 34(2):189–196. https://doi.org/10.1177/0269881119895536
Decressac M, Björklund A (2013) mTOR Inhibition Alleviates L-DOPA-Induced Dyskinesia in Parkinsonian Rats. J Park Dis 3:13–17
Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL151 for Parkinson’s Disease and Launch of Its Engage Parkinson’s disease. 2019. Website. Available online: https://www.globenewswire.com/news-release/2019/09/04/1910858/0/en/Denali-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1b-Study-of-DNL151-for-Parkinson-s-Disease-and-Launch-ofIts-Engage-Parkinson-s-Website.html (accessed on 02 June 2022).
Denali Therapeutics Announces Positive Clinical Results from LRRK2 Inhibitor Program for Parkinson’s Disease. 2018. Available online: https://denalitherapeutics.gcs-web.com/node/6741/pdf (accessed on 02 June 2022).
Deng S, Deng X, Song Z, Xiu X, Guo Y, Xiao J, Deng H (2015) Systematic Genetic Analysis of the SMPD1 Gene in Chinese Patients with Parkinson’s Disease. Mol Neurobiol 53:5025–5029
Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Schäfer H, Bötzel K, Daniels C, Deutschländer A, Dillmann U, Eisner W, Gruber D, Hamel W, Herzog J, Hilker R, Klebe S, Kloss M, Koy J, Krause M, Kupsch A, Lorenz D, Lorenzl S, Mehdorn HM, Moringlane JR, Oertel W, Pinsker MO, Reichmann H, Reuss A, Schneider GH, Schnitzler A, Steude U, Sturm V, Timmermann L, Tronnier V, Trottenberg T, Wojtecki L, Wolf E, Poewe W, Voges J, German Parkinson Study Group, Neurostimulation Section (2006) A randomized trial of deep-brain stimulation for Parkinson’s disease. N Engl J Med. 355(9):896–908. https://doi.org/10.1056/NEJMoa060281. (Erratum in: N Engl J Med. 2006 Sep 21;355(12):1289)
Díaz ML (2019) Regenerative medicine: could Parkinson’s be the first neurodegenerative disease to be cured? Future Sci OA 5(9):FSO418. https://doi.org/10.2144/fsoa-2019-0035
Dong RF, Zhang B, Tai LW, Liu HM, Shi FK, Liu NN (2018) The Neuroprotective Role of MiR-124-3p in a 6-Hydroxydopamine-Induced Cell Model of Parkinson’s Disease via the Regulation of ANAX5. J Cell Biochem 119(1):269–277. https://doi.org/10.1002/jcb.26170
Dong LG, Lu FF, Zu J, Zhang W, Xu CY, Jin GL, Yang XX, Xiao QH, Cui CC, Xu R, Zhou S, Zhu JN, Shen T, Cui GY (2020) MiR-133b inhibits MPP+-induced apoptosis in Parkinson’s disease model by inhibiting the ERK1/2 signaling pathway. Eur Rev Med Pharmacol Sci 24(21):11192–11198. https://doi.org/10.26355/eurrev_202011_23607
Dong Y, Xiong J, Ji L, Xue X (2021) MiR-421 Aggravates Neurotoxicity and Promotes Cell Death in Parkinson’s Disease Models by Directly Targeting MEF2D. Neurochem Res 46(2):299–308. https://doi.org/10.1007/s11064-020-03166-0
Dorsey ER, Bloem BR (2018) The Parkinson Pandemic-A Call to Action. JAMA Neurol 75(1):9–10. https://doi.org/10.1001/jamaneurol.2017.3299
Doxakis E (2010) Post-transcriptional regulation of alpha-synuclein expression by mir-7 and mir-153. J Biol Chem 285(17):12726–34. https://doi.org/10.1074/jbc.M109.086827
Du RW, Bu WG (2021) Simvastatin Prevents Neurodegeneration in the MPTP Mouse Model of Parkinson’s Disease via Inhibition of A1 Reactive Astrocytes. NeuroImmunoModulation 28(2):82–89. https://doi.org/10.1159/000513678
El Salam RA, Safar MM (2015) Neuroprotective effects of vildagliptin in rat rotenone Parkinson’s disease model: Role of RAGE-NFκB and Nrf2-antioxidant signaling pathways. J Neurochem 133:700–707
Emamzadeh FN, Surguchov A (2018) Parkinson’s Disease: Biomarkers, Treatment, and Risk Factors. Front Neurosci 12:612. https://doi.org/10.3389/fnins.2018.00612
Engelender S (2008) Ubiquitination of alpha-synuclein and autophagy in Parkinson’s disease. Autophagy 4(3):372–374. https://doi.org/10.4161/auto.5604
Eschbach J, Von Einem B, Muller K, Bayer H, Scheffold A, Morrison BE, Rudolph KL, Thal DR, Witting A, Weydt P et al (2014) Mutual exacerbation of peroxisome proliferator-activated receptor γ coactivator 1α deregulation and α-synuclein oligomerization. Ann Neurol 77:15–32
Fell MJ, Mirescu C, Basu K, Cheewatrakoolpong B, DeMong DE, Ellis JM, Hyde LA, Lin Y, Markgraf CG, Mei H et al (2015) MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition. J Pharmacol Exp Ther 355:397–409
Fernández-Santiago R, Iranzo A, Gaig C, Serradell M, Fernández M, Tolosa E, Santamaría J, Ezquerra M (2015) MicroRNA association with synucleinopathy conversion in rapid eye movement behavior disorder. Ann Neurol 77(5):895–901. https://doi.org/10.1002/ana.24384
Ferretta A, Gaballo A, Tanzarella P, Piccoli C, Capitanio N, Nico B, Annese T, Di Paola M, Dell’Aquila C, De Mari M et al (2014) Effect of resveratrol on mitochondrial function: Implications in parkin-associated familiar Parkinson’s disease. Biochim Biophys Acta (BBA)—Mol Basis Dis 1842:902–915
Fields CR, Bengoa-Vergniory N, Wade-Martins R (2019) Targeting Alpha-Synuclein as a Therapy for Parkinson’s Disease. Front Mol Neurosci 5(12):299. https://doi.org/10.3389/fnmol.2019.00299
Fink JS, Weaver DR, Rivkees SA, Peterfreund RA, Pollack AE, Adler EM, Reppert SM (1992) Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. Brain Res Mol Brain Res 14(3):186–195. https://doi.org/10.1016/0169-328x(92)90173-9
Follett KA, Weaver FM, Stern M, Hur K, Harris CL, Luo P, Marks WJ Jr, Rothlind J, Sagher O, Moy C, Pahwa R, Burchiel K, Hogarth P, Lai EC, Duda JE, Holloway K, Samii A, Horn S, Bronstein JM, Stoner G, Starr PA, Simpson R, Baltuch G, De Salles A, Huang GD, Reda DJ, CSP 468 Study Group (2010) Pallidal versus subthalamic deep-brain stimulation for Parkinson’s disease. N Engl J Med. 362(22):2077–91. https://doi.org/10.1056/NEJMoa0907083
Foo JN, Liany H, Bei JX, Yu XQ, Liu J, Au WL, Prakash KM, Tan LC, Tan EK (2013) Rare lysosomal enzyme gene SMPD1 variant (p.R591C) associates with Parkinson's disease. Neurobiol Aging 34(12):2890.e13–2890.e15. https://doi.org/10.1016/j.neurobiolaging.2013.06.010.
Fowler A, Torres-Yaghi Y, Pagan F, Hebron M, Wilmarth B, Lawler A, Mundel E, Yusuf N, Starr J, Anjum M et al (2020) Nilotinib alters microRNAs that regulate specific autophagy and ubiquitination genes in the CSF of individuals with Parkinson’s disease (5357). Neurology 94:5357
Francelle L, Outeiro TF, Rappold GA (2020) Inhibition of HDAC6 activity protects dopaminergic neurons from alpha-synuclein toxicity. Sci Rep 10(1):6064. https://doi.org/10.1038/s41598-020-62678-5
Fronczek R, Overeem S, Lee SY, Hegeman IM, van Pelt J, van Duinen SG, Lammers GJ, Swaab DF (2007) Hypocretin (orexin) loss in Parkinson’s disease. Brain 130(Pt 6):1577–1585. https://doi.org/10.1093/brain/awm090
Fuji RN, Flagella M, Baca M, Baptista MAS, Brodbeck J, Chan BK, Fiske BK, Honigberg L, Jubb AM, Katavolos P et al (2015) Effect of selective LRRK2 kinase inhibition on nonhuman primate lung. Sci Transl Med 7:273ra15
Fuxe K, Agnati LF, Jacobsen K, Hillion J, Canals M, Torvinen M, Tinner-Staines B, Staines W, Rosin D, Terasmaa A, Popoli P, Leo G, Vergoni V, Lluis C, Ciruela F, Franco R, Ferré S (2003) Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson’s disease. Neurology 61(11 Suppl 6):S19-23. https://doi.org/10.1212/01.wnl.0000095206.44418.5c
Gao S, Duan C, Gao G, Wang X, Yang H (2015) Alpha-synuclein overexpression negatively regulates insulin receptor substrate 1 by activating mTORC1/S6K1 signaling. Int J Biochem Cell Biol 64:25–33
Gardet A, Benita Y, Li C, Sands BE, Ballester I, Stevens C, Korzenik JR, Rioux JD, Daly MJ, Xavier RJ et al (2010) LRRK2 Is Involved in the IFN-γ Response and Host Response to Pathogens. J Immunol 185:5577–5585
Garitaonandia I, Gonzalez R, Sherman G, Semechkin A, Evans A, Kern R (2018) Novel Approach to Stem Cell Therapy in Parkinson’s Disease. Stem Cells Dev 27(14):951–957. https://doi.org/10.1089/scd.2018.0001
Gasca-Salas C, García-Lorenzo D, Garcia-Garcia D, Clavero P, Obeso JA, Lehericy S, Rodríguez-Oroz MC (2019) Parkinson’s disease with mild cognitive impairment: severe cortical thinning antedates dementia. Brain Imaging Behav 13(1):180–188. https://doi.org/10.1007/s11682-017-9751-6
Geng L, Liu W, Chen Y (2017) miR-124–3p attenuates MPP+-induced neuronal injury by targeting STAT3 in SH-SY5Y cells. Exp Biol Med (Maywood). 242(18):1757–1764. https://doi.org/10.1177/1535370217734492
Gentry EG, Henderson BW, Arrant AE, Gearing M, Feng Y, Riddle NC, Herskowitz JH (2016) Rho Kinase Inhibition as a Therapeutic for Progressive Supranuclear Palsy and Corticobasal Degeneration. J. Neurosci. 36:1316–1323 [CrossRef]
Gerlach M, Bartoszyk GD, Riederer P, Dean O, van den Buuse M (2011) Role of dopamine D3 and serotonin 5-HT 1A receptors in L: -DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson’s disease. J Neural Transm (Vienna) 118(12):1733–1742. https://doi.org/10.1007/s00702-010-0571-8
Ghazi Sherbaf F, Mohajer B, Ashraf-Ganjouei A, Mojtahed Zadeh M, Javinani A, Sanjari Moghaddam H, Shirin Shandiz M, Aarabi MH (2018) Serum Insulin-Like Growth Factor-1 in Parkinson’s Disease; Study of Cerebrospinal Fluid Biomarkers and White Matter Microstructure. Front Endocrinol (Lausanne) 2(9):608. https://doi.org/10.3389/fendo.2018.00608
Ghiglieri V, Mineo D, Vannelli A, Cacace F, Mancini M, Pendolino V, Napolitano F, di Maio A, Mellone M, Stanic J, Tronci E, Fidalgo C, Stancampiano R, Carta M, Calabresi P, Gardoni F, Usiello A, Picconi B (2016) Modulation of serotonergic transmission by eltoprazine in L-DOPA-induced dyskinesia: Behavioral, molecular, and synaptic mechanisms. Neurobiol Dis 86:140–153. https://doi.org/10.1016/j.nbd.2015.11.022
Gold L, Ayers D, Bertino J, Bock C, Bock A, Brody EN, Carter J, Dalby AB, Eaton BE, Fitzwater T, Flather D, Forbes A, Foreman T, Fowler C, Gawande B, Goss M, Gunn M, Gupta S, Halladay D, Heil J, Heilig J, Hicke B, Husar G, Janjic N, Jarvis T, Jennings S, Katilius E, Keeney TR, Kim N, Koch TH, Kraemer S, Kroiss L, Le N, Levine D, Lindsey W, Lollo B, Mayfield W, Mehan M, Mehler R, Nelson SK, Nelson M, Nieuwlandt D, Nikrad M, Ochsner U, Ostroff RM, Otis M, Parker T, Pietrasiewicz S, Resnicow DI, Rohloff J, Sanders G, Sattin S, Schneider D, Singer B, Stanton M, Sterkel A, Stewart A, Stratford S, Vaught JD, Vrkljan M, Walker JJ, Watrobka M, Waugh S, Weiss A, Wilcox SK, Wolfson A, Wolk SK, Zhang C, Zichi D (2010) Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS One 5(12):e15004. https://doi.org/10.1371/journal.pone.0015004
Goldman JG, Holden S (2014) Treatment of psychosis and dementia in Parkinson’s disease. Curr Treat Options Neurol 16(3):281. https://doi.org/10.1007/s11940-013-0281-2
Gomperts SN, Locascio JJ, Rentz D, Santarlasci A, Marquie M, Johnson KA, Growdon JH (2013) Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology. 80(1):85–91. https://doi.org/10.1212/WNL.0b013e31827b1a07
Gong X, Wang H, Ye Y, Shu Y, Deng Y, He X, Lu G, Zhang S (2016) miR-124 regulates cell apoptosis and autophagy in dopaminergic neurons and protects them by regulating AMPK/mTOR pathway in Parkinson’s disease. Am J Transl Res. 8(5):2127–37
Gouda NA, Elkamhawy A, Cho J (2022) Emerging Therapeutic Strategies for Parkinson’s Disease and Future Prospects: A 2021 Update. Biomedicines 10(2):371
Grabli D, Karachi C, Folgoas E, Monfort M, Tande D, Clark S, Civelli O, Hirsch EC, François C (2013) Gait disorders in parkinsonian monkeys with pedunculopontine nucleus lesions: a tale of two systems. J Neurosci 33(29):11986–11993. https://doi.org/10.1523/JNEUROSCI.1568-13.2013
Gratwicke J, Zrinzo L, Kahan J, Peters A, Beigi M, Akram H, Hyam J, Oswal A, Day B, Mancini L, Thornton J, Yousry T, Limousin P, Hariz M, Jahanshahi M, Foltynie T (2018) Bilateral Deep Brain Stimulation of the Nucleus Basalis of Meynert for Parkinson Disease Dementia: A Randomized Clinical Trial. JAMA Neurol 75(2):169–178. https://doi.org/10.1001/jamaneurol.2017.3762
Grégoire L, Samadi P, Graham J, Bédard PJ, Bartoszyk GD, Di Paolo T (2009) Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys. Parkinsonism Relat Disord 15(6):445–452. https://doi.org/10.1016/j.parkreldis.2008.11.001
Grondin R, Bédard PJ, Hadj Tahar A, Grégoire L, Mori A, Kase H (1999) Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Neurology 52(8):1673–1677. https://doi.org/10.1212/wnl.52.8.1673
Gronich N, Abernethy DR, Auriel E, Lavi I, Rennert G, Saliba W (2018) β2-adrenoceptor agonists and antagonists and risk of Parkinson’s disease. Mov Disord 33:1465–1471
Grossi I, Radeghieri A, Paolini L, Porrini V, Pilotto A, Padovani A, Marengoni A, Barbon A, Bellucci A, Pizzi M, Salvi A, De Petro G (2021) MicroRNA-34a-5p expression in the plasma and in its extracellular vesicle fractions in subjects with Parkinson’s disease: An exploratory study. Int J Mol Med 47(2):533–546. https://doi.org/10.3892/ijmm.2020.4806
Gu M, Iravani MM, Cooper JM, King D, Jenner P, Schapira AH (2004) Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. J Neurochem 91(5):1075–1081. https://doi.org/10.1111/j.1471-4159.2004.02804.x. (Erratum in: J Neurochem. 2005 Jan;92(1):215. Irvani, M [corrected to Iravani, MM])
Hacker ML, DeLong MR, Turchan M, Heusinkveld LE, Ostrem JL, Molinari AL, Currie AD, Konrad PE, Davis TL, Phibbs FT, Hedera P, Cannard KR, Drye LT, Sternberg AL, Shade DM, Tonascia J, Charles D (2018) Effects of deep brain stimulation on rest tremor progression in early stage Parkinson disease. Neurology. 91(5):e463–e471. https://doi.org/10.1212/WNL.0000000000005903
Hamadjida A, Nuara SG, Bédard D, Gaudette F, Beaudry F, Gourdon JC, Huot P (2018) The highly selective 5-HT2A antagonist EMD-281,014 reduces dyskinesia and psychosis in the l-DOPA-treated parkinsonian marmoset. Neuropharmacology 1(139):61–67. https://doi.org/10.1016/j.neuropharm.2018.06.038
Hamm-Alvarez SF, Okamoto CT, Janga SR, Feigenbaum D, Edman MC, Freire D, Shah M, Ghanshani R, Mack WJ, Lew MF (2019) Oligomeric α-synuclein is increased in basal tears of Parkinson’s patients. Biomark Med 13(11):941–952. https://doi.org/10.2217/bmm-2019-0167
Han L, Tang Y, Bai X, Liang X, Fan Y, Shen Y, Huang F, Wang J (2020) Association of the serum microRNA-29 family with cognitive impairment in Parkinson’s disease. Aging (Albany NY) 12(13):13518–13528. https://doi.org/10.18632/aging.103458
He R, Yan X, Guo J, Xu Q, Tang B, Sun Q (2018) Recent Advances in Biomarkers for Parkinson’s Disease. Front Aging Neurosci 11(10):305. https://doi.org/10.3389/fnagi.2018.00305
Heijer JMD, Kruithof AC, van Amerongen G, de Kam ML, Thijssen E, Grievink HW, Moerland M, Walker M, Been K, Skerlj R et al (2021) A randomized single and multiple ascending dose study in healthy volunteers of LTI-291, a centrally penetrant glucocerebrosidase activator. Br J Clin Pharmacol 87:3561–3573
Hernandez DG, Reed X, Singleton AB (2016) Genetics in Parkinson’s disease: Mendelian versus non-Mendelian inheritance. J Neurochem 139:59–74
Herzig MC, Kolly C, Persohn E, Theil D, Schweizer T, Hafner T, Stemmelen C, Troxler TJ, Schmid P, Danner S et al (2011) LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum Mol Genet 20:4209–4223
Hickey P, Stacy M (2016) Deep Brain Stimulation: A Paradigm Shifting Approach to Treat Parkinson’s Disease. Front Neurosci 28(10):173. https://doi.org/10.3389/fnins.2016.00173
Hill-Burns EM, Ross OA, Wissemann WT, Soto-Ortolaza AI, Zareparsi S, Siuda J, Lynch T, Wszolek ZK, Silburn PA, Mellick GD et al (2016) Identification of genetic modifiers of age-at-onset for familial Parkinson’s disease. Hum Mol Genet 25:3849–3862
Hoeffer CA, Klann E (2010) mTOR signaling: At the crossroads of plasticity, memory and disease. Trends Neurosci 33:67–75
Hopfner F, Wod M, Höglinger GU, Blaabjerg M, Rösler TW, Kuhlenbäumer G, Christensen K, Deuschl G, Pottegård A (2019) Use of β2-adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease. Neurology 93(2):e135–e142. https://doi.org/10.1212/WNL.0000000000007694
Hopkins CR, Lindsley CW, Niswender CM (2009) mGluR4-positive allosteric modulation as potential treatment for Parkinson’s disease. Future Med Chem 1(3):501–513. https://doi.org/10.4155/fmc.09.38
Hopp SC (2020) Targeting microglia L-type voltage-dependent calcium channels for the treatment of central nervous system disorders. J Neurosci Res 99:141–162
Hopp S, Royer S, D’Angelo HM, Kaercher RM, Fisher DA, Wenk GL (2014) Differential Neuroprotective and Anti-Inflammatory Effects of L-Type Voltage Dependent Calcium Channel and Ryanodine Receptor Antagonists in the Substantia Nigra and Locus Coeruleus. J Neuroimmune Pharmacol 10:35–44
Hoss AG, Labadorf A, Beach TG, Latourelle JC, Myers RH (2016) microRNA Profiles in Parkinson’s Disease Prefrontal Cortex. Front Aging Neurosci 1(8):36. https://doi.org/10.3389/fnagi.2016.00036
Howlett EH, Jensen N, Belmonte F, Zafar F, Hu X, Kluss J, Schüle B, Kaufman BA, Greenamyre JT, Sanders LH (2017) LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson’s disease. Hum Mol Genet 26:4340–4351
Hu YB, Zhang YF, Wang H, Ren RJ, Cui HL, Huang WY, Cheng Q, Chen HZ, Wang G (2019) miR-425 deficiency promotes necroptosis and dopaminergic neurodegeneration in Parkinson’s disease. Cell Death Dis 10(8):589. https://doi.org/10.1038/s41419-019-1809-5
Huang C, Tang C, Feigin A, Lesser M, Ma Y, Pourfar M, Dhawan V, Eidelberg D (2007) Changes in network activity with the progression of Parkinson’s disease. Brain 130(Pt 7):1834–46. https://doi.org/10.1093/brain/awm086
Hunot S, Brugg B, Ricard D, Michel PP, Muriel M-P, Ruberg M, Faucheux BA, Agid Y, Hirsch E (1997) Nuclear translocation of NF-B is increased in dopaminergic neurons of patients with Parkinson disease. Proc Natl Acad Sci USA 94:7531–7536
Huot P, Johnston TH, Fox SH, Newman-Tancredi A, Brotchie JM (2015) The highly-selective 5-HT(1A) agonist F15599 reduces L-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque. Neuropharmacology 97:306–311. https://doi.org/10.1016/j.neuropharm.2015.05.033
Iderberg H, McCreary AC, Varney MA, Cenci MA, Newman-Tancredi A (2015) Activity of serotonin 5-HT(1A) receptor “biased agonists” in rat models of Parkinson’s disease and L-DOPA-induced dyskinesia. Neuropharmacology 93:52–67. https://doi.org/10.1016/j.neuropharm.2015.01.012
Ilijic E, Guzman J, Surmeier D (2011) The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson’s disease. Neurobiol Dis 43:364–371
Iravani MM, Jackson MJ, Kuoppamäki M, Smith LA, Jenner P (2003) 3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates. J Neurosci 23(27):9107–9115. https://doi.org/10.1523/JNEUROSCI.23-27-09107.2003
Iravani MM, Haddon CO, Cooper JM, Jenner P, Schapira AH (2006) Pramipexole protects against MPTP toxicity in non-human primates. J Neurochem 96(5):1315–1321. https://doi.org/10.1111/j.1471-4159.2005.03625.x
Ishii T, Kinoshita KI, Muroi Y (2019) Serotonin 5-HT4 Receptor Agonists Improve Facilitation of Contextual Fear Extinction in an MPTP-Induced Mouse Model of Parkinson’s Disease. Int J Mol Sci 20(21):5340. https://doi.org/10.3390/ijms20215340
Iwashita A, Muramatsu Y, Yamazaki T, Muramoto M, Kita Y, Yamazaki S, Mihara K, Moriguchi A, Matsuoka N (2006) Neuroprotective Efficacy of the Peroxisome Proliferator-Activated Receptor δ-Selective Agonists in Vitro and in Vivo. J Pharmacol Exp Ther 320:1087–1096
Iyer M, Subramaniam MD, Venkatesan D, Cho S-G, Ryding M, Meyer M, Vellingiri B (2020) Role of RhoA-ROCK signaling in Parkinson’s disease. Eur J Pharmacol 894:173815
Jankovic J, Tan EK (2020) Parkinson’s disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry 91(8):795–808. https://doi.org/10.1136/jnnp-2019-322338
Jankovic J, Goodman I, Safirstein B, Marmon TK, Schenk DB, Koller M, Zago W, Ness DK, Griffith SG, Grundman M, Soto J, Ostrowitzki S, Boess FG, Martin-Facklam M, Quinn JF, Isaacson SH, Omidvar O, Ellenbogen A, Kinney GG (2018) Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol 75(10):1206–1214. https://doi.org/10.1001/jamaneurol.2018.1487
Jenner P (2004) Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson’s disease. Neurology 63(7 Suppl 2):S13-22. https://doi.org/10.1212/wnl.63.7_suppl_2.s13
Jenner P (2005) Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson’s disease. Expert Opin Investig Drugs 14(6):729–738. https://doi.org/10.1517/13543784.14.6.729
Jenner P, McCreary AC, Scheller DK (2011) Continuous drug delivery in early- and late-stage Parkinson’s disease as a strategy for avoiding dyskinesia induction and expression. J Neural Transm (Vienna) 118(12):1691–1702. https://doi.org/10.1007/s00702-011-0703-9
Jęśko H, Lenkiewicz AM, Adamczyk A (2017) Treatments and compositions targeting α-synuclein: a patent review (2010–2016). Expert Opin Ther Pat 27(4):427–438. https://doi.org/10.1080/13543776.2017.1261112
Ji K, Zhao Y, Yu T, Wang Z, Gong H, Yang X, Liu Y, Huang K (2016) Inhibition effects of tanshinone on the aggregation of α-synuclein. Food Funct 7(1):409–416. https://doi.org/10.1039/c5fo00664c
Jiang Q, Heneka M, Landreth GE (2008) The Role of Peroxisome Proliferator-Activated Receptor-γ (PPARγ) in Alzheimer’s Disease. CNS Drugs 22:1–14
Jiang T-F, Zhang Y-J, Zhou H-Y, Wang H-M, Tian L-P, Liu J, Ding J-Q, Chen S-D (2013) Curcumin Ameliorates the Neurodegenerative Pathology in A53T α-synuclein Cell Model of Parkinson’s Disease Through the Downregulation of mTOR/p70S6K Signaling and the Recovery of Macroautophagy. J Neuroimmune Pharmacol 8:356–369
Jiang DQ, Wang HK, Wang Y, Li MX, Jiang LL, Wang Y (2020) Rasagiline combined with levodopa therapy versus levodopa monotherapy for patients with Parkinson’s disease: a systematic review. Neurol Sci 41(1):101–109. https://doi.org/10.1007/s10072-019-04050-8
Jiang H, Kang S-U, Zhang S, Karuppagounder S, Xu J, Lee Y-K, Kang B-G, Lee Y, Zhang J, Pletnikova O et al (2016) Adult Conditional Knockout of PGC-1α Leads to Loss of Dopamine Neurons. eNEURO 3, ENEURO.0183–16.2016
Joers V, Tansey MG, Mulas G, Carta AR (2016) Microglial phenotypes in Parkinson’s disease and animal models of the disease. Prog Neurobiol 155:57–75
Johnston TH, Huot P, Fox SH, Wakefield JD, Sykes KA, Bartolini WP, Milne GT, Pearson JP, Brotchie JM (2011) Fatty acid amide hydrolase (FAAH) inhibition reduces L-3,4-dihydroxyphenylalanine-induced hyperactivity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned non-human primate model of Parkinson’s disease. J Pharmacol Exp Ther 336(2):423–430. https://doi.org/10.1124/jpet.110.169532
Kachroo A, Orlando LR, Grandy DK, Chen JF, Young AB, Schwarzschild MA (2005) Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice. J Neurosci 25(45):10414–10419. https://doi.org/10.1523/JNEUROSCI.3660-05.2005
Kadowaki Horita T, Kobayashi M, Mori A, Jenner P, Kanda T (2013) Effects of the adenosine A2A antagonist istradefylline on cognitive performance in rats with a 6-OHDA lesion in prefrontal cortex. Psychopharmacology 230(3):345–352. https://doi.org/10.1007/s00213-013-3158-x
Kalia SK, Sankar T, Lozano AM (2013) Deep brain stimulation for Parkinson’s disease and other movement disorders. Curr Opin Neurol 26(4):374–380. https://doi.org/10.1097/WCO.0b013e3283632d08
Kanagaraj N, Beiping H, Dheen ST, Tay SS (2014) Downregulation of miR-124 in MPTP-treated mouse model of Parkinson’s disease and MPP iodide-treated MN9D cells modulates the expression of the calpain/cdk5 pathway proteins. Neuroscience 11(272):167–179. https://doi.org/10.1016/j.neuroscience.2014.04.039
Kanda T, Jenner P (2020) Can adenosine A2A receptor antagonists modify motor behavior and dyskinesia in experimental models of Parkinson’s disease? Parkinsonism Relat Disord 80(Suppl 1):S21–S27. https://doi.org/10.1016/j.parkreldis.2020.09.026
Kandiah N, Zainal NH, Narasimhalu K, Chander RJ, Ng A, Mak E, Au WL, Sitoh YY, Nadkarni N, Tan LC (2014) Hippocampal volume and white matter disease in the prediction of dementia in Parkinson’s disease. Parkinsonism Relat Disord 20(11):1203–1208. https://doi.org/10.1016/j.parkreldis.2014.08.024
Karuppagounder SS, Brahmachari S, Lee Y, Dawson VL, Dawson TM, Ko HS (2014) The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson’s disease. Sci Rep 2(4):4874. https://doi.org/10.1038/srep04874
Kim DS, Choi H-I, Wang Y, Luo Y, Hoffer BJ, Greig NH (2017) A New Treatment Strategy for Parkinson’s Disease through the Gut-Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway. Cell Transplant 26:1560–1571
Kreisler A, Gelé P, Wiart J-F, Lhermitte M, Destée A, Bordet R (2007) Lipid-lowering drugs in the MPTP mouse model of Parkinson’s disease: Fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not. Brain Res 1135:77–84
Kujirai H, Itaya S, Ono Y, Takahashi M, Inaba A, Shimo Y, Hattori N, Orimo S (2020) A Study for Expanding Application Sites for Rotigotine Transdermal Patch. Parkinsons Dis 10(2020):5892163. https://doi.org/10.1155/2020/5892163
Kurkowska-Jastrzebska I, Babiuch M, Joniec I, Przybyłkowski A, Członkowski A (2002) Indomethacin protects against neurodegeneration caused by MPTP intoxication in mice. Int Immunopharmacol 2:1213–1218
Kwan C, Frouni I, Bédard D, Hamadjida A, Huot P (2021) Granisetron, a selective 5-HT3 antagonist, reduces L-3,4-dihydroxyphenylalanine-induced abnormal involuntary movements in the 6-hydroxydopamine-lesioned rat. Behav Pharmacol 32(1):43–53. https://doi.org/10.1097/FBP.0000000000000601
Kwan C, Nuara SG, Bédard D, Gaudette F, Gourdon JC, Beaudry F, Huot P (2021b) Selective blockade of the 5-HT3 receptor acutely alleviates dyskinesia and psychosis in the parkinsonian marmoset. Neuropharmacology. 182:108386. https://doi.org/10.1016/j.neuropharm.2020.108386
Lardenoije R, Iatrou A, Kenis G, Kompotis K, Steinbusch HW, Mastroeni D, Coleman P, Lemere CA, Hof PR, van den Hove DL et al (2015) The epigenetics of aging and neurodegeneration. Prog Neurobiol 131:21–64
Laureys G, Clinckers R, Gerlo S, Spooren A, Wilczak N, Kooijman R, Smolders I, Michotte Y, De Keyser J (2010) Astrocytic β2-adrenergic receptors: From physiology to pathology. Prog Neurobiol 91:189–199
LaValley NJ, Slone SR, Ding H, West A, Yacoubian TA (2015) 14-3-3 Proteins regulate mutant LRRK2 kinase activity and neurite shortening. Hum Mol Genet 25:109–122
Lazzara CA, Kim Y-H (2015) Potential application of lithium in Parkinson’s and other neurodegenerative diseases. Front Neurosci 9:403
Le Poul E, Boléa C, Girard F, Poli S, Charvin D, Campo B, Bortoli J, Bessif A, Luo B, Koser AJ, Hodge LM, Smith KM, DiLella AG, Liverton N, Hess F, Browne SE, Reynolds IJ (2012) A potent and selective metabotropic glutamate receptor 4 positive allosteric modulator improves movement in rodent models of Parkinson’s disease. J Pharmacol Exp Ther 343(1):167–177. https://doi.org/10.1124/jpet.112.196063
Lee Y, Stevens DA, Kang S-U, Jiang H, Lee Y-I, Ko HS, Scarffe LA, Umanah GE, Kang H, Ham S et al (2017) PINK1 Primes Parkin-Mediated Ubiquitination of PARIS in Dopaminergic Neuronal Survival. Cell Rep 18:918–932
Leftin A, Job C, Beyer K, Brown MF (2013) Solid-State 13C NMR Reveals Annealing of Raft-Like Membranes Containing Cholesterol by the Intrinsically Disordered Protein α-Synuclein. J Mol Biol 425:2973–2987
Leggio L, Vivarelli S, L’Episcopo F et al (2017) microRNAs in Parkinson’s Disease: From Pathogenesis to Novel Diagnostic and Therapeutic Approaches. Int J Mol Sci 18(12):2698. https://doi.org/10.3390/ijms18122698
Leiva-Rodríguez T, Romeo-Guitart D, Marmolejo-Martínez-Artesero S, Herrando-Grabulosa M, Bosch A, Forés J, Casas C (2018) ATG5 overexpression is neuroprotective and attenuates cytoskeletal and vesicle-trafficking alterations in axotomized motoneurons. Cell Death Dis 9(6):626. https://doi.org/10.1038/s41419-018-0682-y
Levenson JM, Schroeter S, Carroll JC, Cullen V, Asp E, Proschitsky M, Chung CH-Y, Gilead S, Nadeem M, Dodiya HB et al (2016) NPT088 reduces both amyloid-β and tau pathologies in transgenic mice. Alzheimer’s Dement Transl Res Clin Interv 2:141–155
Lewis J, Melrose H, Bumcrot D, Hope A, Zehr C, Lincoln S, Braithwaite A, He Z, Ogholikhan S, Hinkle K, Kent C, Toudjarska I, Charisse K, Braich R, Pandey RK, Heckman M, Maraganore DM, Crook J, Farrer MJ (2008) In vivo silencing of alpha-synuclein using naked siRNA. Mol Neurodegener 1(3):19. https://doi.org/10.1186/1750-1326-3-19
LeWitt PA, Aradi SD, Hauser RA, Rascol O (2020) The challenge of developing adenosine A2A antagonists for Parkinson disease: Istradefylline, preladenant, and tozadenant. Parkinsonism Relat Disord 80(Suppl 1):S54–S63. https://doi.org/10.1016/j.parkreldis.2020.10.027
Li Y, Hu X, Liu Y, Bao Y, An L (2009a) Nimodipine protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation. Neuropharmacology 56:580–589
Li Y, Perry T, Kindy MS, Harvey BK, Tweedie D, Holloway HW, Powers K, Shen H, Egan JM, Sambamurti K et al (2009b) GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci USA 106:1285–1290
Li Y, Tweedie D, Mattson MP, Holloway HW, Greig NH (2010) Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells. J Neurochem 113:1621–1631
Li Y, Wu K-J, Yu S-J, Tamargo IA, Wang Y, Greig NH (2016) Neurotrophic and neuroprotective effects of oxyntomodulin in neuronal cells and a rat model of stroke. Exp Neurol 288:104–113
Li L, Xu J, Wu M, Hu JM (2018) Protective role of microRNA-221 in Parkinson’s disease. Bratisl Lek Listy 119(1):22–27. https://doi.org/10.4149/BLL_2018_005
Li L, Hui Y, Wu Z, Qiao H, Guo F, Ma B, Zhang Q (2020a) Activation and blockade of 5-HT6 receptor in the medial septum-diagonal band recover working memory in the hemiparkinsonian rats. Brain Res 1748:147072. https://doi.org/10.1016/j.brainres.2020.147072
Li H, Yu L, Li M, Chen X, Tian Q, Jiang Y, Li N (2020b) MicroRNA-150 serves as a diagnostic biomarker and is involved in the inflammatory pathogenesis of Parkinson’s disease. Mol Genet Genomic Med 8(4):e1189. https://doi.org/10.1002/mgg3.1189
Lill CM (2016) Genetics of Parkinson’s disease. Mol Cell Probes 30:386–396
Lim NS, Swanson CR, Cherng HR, Unger TL, Xie SX, Weintraub D, Marek K, Stern MB, Siderowf A, PARS Investigators; Alzheimer’s Disease Neuroimaging Initiative, Trojanowski JQ, Chen-Plotkin AS (2016) Plasma EGF and cognitive decline in Parkinson’s disease and Alzheimer’s disease. Ann Clin Transl Neurol. 3(5):346–55. https://doi.org/10.1002/acn3.299
Liu J, Yin F, Zheng X, Jing J, Hu Y (2007) Geniposide, a novel agonist for GLP-1 receptor, prevents PC12 cells from oxidative damage via MAP kinase pathway. Neurochem Int 51:361–369
Liu G-H, Qu J, Suzuki K, Nivet E, Li M, Montserrat N, Yi F, Xu X, Ruiz S, Zhang W et al (2012) Progressive degeneration of human neural stem cells caused by pathogenic LRRK2. Nature 491:603–607
Liu J, Chen M, Wang X, Wang Y, Duan C, Gao G, Lu L, Wu X, Wang X, Yang H (2016) Piperine induces autophagy by enhancing protein phosphotase 2A activity in a rotenone-induced Parkinson’s disease model. Oncotarget 7:60823–60843
Liu W, Liu X, Li Y, Zhao J, Liu Z, Hu Z, Wang Y, Yao Y, Miller AW, Su B et al (2017) LRRK2 promotes the activation of NLRC4 inflammasome during Salmonella Typhimurium infection. J Exp Med 214:3051–3066
Liu Y, Sorce S, Nuvolone M, Domange J, Aguzzi A (2018) Lymphocyte activation gene 3 (Lag3) expression is increased in prion infections but does not modify disease progression. Sci Rep 8:14600
Lopez-Cuina M, Guerin PA, Canron MH, Delamarre A, Dehay B, Bezard E, Meissner WG, Fernagut PO (2020) Nilotinib Fails to Prevent Synucleinopathy and Cell Loss in a Mouse Model of Multiple System Atrophy. Mov Disord 35(7):1163–1172. https://doi.org/10.1002/mds.28034
Lopez-Lopez A, Labandeira CM, Labandeira-Garcia JL, Muñoz A (2020) Rho kinase inhibitor fasudil reduces l -DOPA-induced dyskinesia in a rat model of Parkinson’s disease. J Cereb Blood Flow Metab 177:5622–5641
Lu JYD, Su P, Barber JEM, Nash JE, Le AD, Liu F, Wong AHC (2017) The neuroprotective effect of nicotine in Parkinson’s disease models is associated with inhibiting PARP-1 and caspase-3 cleavage. PeerJ 5:e3933. https://doi.org/10.7717/peerj.3933
Lv Q, Zhong Z, Hu B, Yan S, Yan Y, Zhang J, Shi T, Jiang L, Li W, Huang W (2021) MicroRNA-3473b regulates the expression of TREM2/ULK1 and inhibits autophagy in inflammatory pathogenesis of Parkinson disease. J Neurochem 157(3):599–610. https://doi.org/10.1111/jnc.15299
Machado MMF, Bassani TB, Cóppola-Segovia V, Moura ELR, Zanata SM, Andreatini R, Vital MABF (2019) PPAR-γ agonist pioglitazone reduces microglial proliferation and NF-κB activation in the substantia nigra in the 6-hydroxydopamine model of Parkinson’s disease. Pharmacol Rep 71(4):556–564. https://doi.org/10.1016/j.pharep.2018.11.005
Maegawa G, Tropak MB, Buttner JD, Rigat BA, Fuller M, Pandit D, Tang L, Kornhaber GJ, Hamuro Y, Clarke JTR et al (2009) Identification and Characterization of Ambroxol as an Enzyme Enhancement Agent for Gaucher Disease. J Biol Chem 284:23502–23516
Magalhaes J, Gegg ME, Migdalska-Richards A, Schapira AH (2018) Effects of ambroxol on the autophagy-lysosome pathway and mitochondria in primary cortical neurons. Sci Rep 8:1385
Majbour NK, Vaikath NN, van Dijk KD, Ardah MT, Varghese S, Vesterager LB, Montezinho LP, Poole S, Safieh-Garabedian B, Tokuda T, Teunissen CE, Berendse HW, van de Berg WD, El-Agnaf OM (2016) Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease. Mol Neurodegener 19(11):7. https://doi.org/10.1186/s13024-016-0072-9
Mak E, Su L, Williams GB, Firbank MJ, Lawson RA, Yarnall AJ, Duncan GW, Owen AM, Khoo TK, Brooks DJ, Rowe JB, Barker RA, Burn DJ, O’Brien JT (2015) Baseline and longitudinal grey matter changes in newly diagnosed Parkinson’s disease: ICICLE-PD study. Brain 138(Pt 10):2974–86. https://doi.org/10.1093/brain/awv211
Malagelada C, Ryu EJ, Biswas SC, Jackson-Lewis V, Greene LA (2006) RTP801 Is Elevated in Parkinson Brain Substantia Nigral Neurons and Mediates Death in Cellular Models of Parkinson’s Disease by a Mechanism Involving Mammalian Target of Rapamycin Inactivation. J Neurosci 26:9996–10005
Malagelada C, Jin ZH, Jackson-Lewis V, Przedborski S, Greene LA (2010) Rapamycin Protects against Neuron Death in In Vitro and In Vivo Models of Parkinson’s Disease. J Neurosci 30:1166–1175
Malek N (2019) Deep Brain Stimulation in Parkinson’s Disease. Neurol India. 67(4):968–978. https://doi.org/10.4103/0028-3886.266268
Mao X, Ou MT, Karuppagounder SS, Kam T-I, Yin X, Xiong Y, Ge P, Umanah GE, Brahmachari S, Shin J-H et al (2016) Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science 353
Marin C, Aguilar E, Rodríguez-Oroz MC, Bartoszyk GD, Obeso JA (2009) Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats. Psychopharmacology 204(2):241–250. https://doi.org/10.1007/s00213-008-1452-9
Marino MJ, Williams DL Jr, O’Brien JA, Valenti O, McDonald TP, Clements MK, Wang R, DiLella AG, Hess JF, Kinney GG, Conn PJ (2003) Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson’s disease treatment. Proc Natl Acad Sci U S A 100(23):13668–73. https://doi.org/10.1073/pnas.1835724100
Maruyama W, Takahashi T, Youdim M, Naoi M (2002) The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J Neural Transm (Vienna) 109(4):467–481. https://doi.org/10.1007/s007020200038
Matsuo K, Cheng A, Yabuki Y, Takahata I, Miyachi H, Fukunaga K (2019) Inhibition of MPTP-induced α-synuclein oligomerization by fatty acid-binding protein 3 ligand in MPTP-treated mice. Neuropharmacology 15(150):164–174. https://doi.org/10.1016/j.neuropharm.2019.03.029
Mazzulli JR, Xu Y-H, Sun Y, Knight AL, McLean PJ, Caldwell GA, Sidransky E, Grabowski GA, Krainc D (2011) Gaucher Disease Glucocerebrosidase and α-Synuclein Form a Bidirectional Pathogenic Loop in Synucleinopathies. Cell 146:37–52
McCormack AL, Mak SK, Henderson JM, Bumcrot D, Farrer MJ, Di Monte DA (2010) Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra. PLoS One 5(8):e12122. https://doi.org/10.1371/journal.pone.0012122
Michelson D, Grundman M, Magnuson K, Fisher R, Levenson JM, Aisen P, Marek K, Gray M, Hefti F (2019) Randomized, placebo controlled trial of NPT088, a phage-derived, amyloid-targeted treatment for Alzheimer’s disease. J Prev Alzheimer’s Dis 6:228–231
Miñones-Moyano E, Porta S, Escaramís G, Rabionet R, Iraola S, Kagerbauer B, Espinosa-Parrilla Y, Ferrer I, Estivill X, Martí E (2011) MicroRNA profiling of Parkinson’s disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function. Hum Mol Genet 20(15):3067–3078. https://doi.org/10.1093/hmg/ddr210
Mischley LK, Allen J, Bradley R (2012) Coenzyme Q10 deficiency in patients with Parkinson’s disease. J Neurol Sci. 318(1–2):72–5. https://doi.org/10.1016/j.jns.2012.03.023
Mischley LK, Standish LJ, Weiss NS, Padowski JM, Kavanagh TJ, White CC, Rosenfeld ME (2016) Glutathione as a Biomarker in Parkinson’s Disease: Associations with Aging and Disease Severity. Oxid Med Cell Longev 2016:9409363. https://doi.org/10.1155/2016/9409363
Mishra A, Goel RK (2016) Chronic 5-HT3 receptor antagonism ameliorates seizures and associated memory deficit in pentylenetetrazole-kindled mice. Neuroscience 17(339):319–328. https://doi.org/10.1016/j.neuroscience.2016.10.010
Mishra A, Goel RK (2019) Modulatory Effect of Serotonergic System in Pentylenetetrazole-Induced Seizures and Associated Memory Deficit: Role of 5-HT1A and 5-HT2A/2C. J Epilepsy Res 9(2):119–125. https://doi.org/10.14581/jer.19012
Mishra A, Bandopadhyay R, Singh PK, Mishra PS, Sharma N, Khurana N (2021a) Neuroinflammation in neurological disorders: pharmacotherapeutic targets from bench to bedside. Metab Brain Dis 36(7):1591–1626. https://doi.org/10.1007/s11011-021-00806-4
Mishra A, Mishra PS, Bandopadhyay R, Khurana N, Angelopoulou E, Paudel YN, Piperi C (2021b) Neuroprotective Potential of Chrysin: Mechanistic Insights and Therapeutic Potential for Neurological Disorders. Molecules 26(21):6456. https://doi.org/10.3390/molecules26216456
Mittal S, Bjørnevik K, Im DS, Flierl A, Dong X, Locascio JJ, Abo KM, Long E, Jin M, Xu B, Xiang YK, Rochet JC, Engeland A, Rizzu P, Heutink P, Bartels T, Selkoe DJ, Caldarone BJ, Glicksman MA, Khurana V, Schüle B, Park DS, Riise T, Scherzer CR (2017) β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson's disease. Science 357(6354):891–898. https://doi.org/10.1126/science.aaf3934.
Moehle M, Webber PJ, Tse T, Sukar N, Standaert D, DeSilva TM, Cowell R, West AB (2012) LRRK2 Inhibition Attenuates Microglial Inflammatory Responses. J Neurosci 32:1602–1611
Monaco D, Berg D, Thomas A, Di Stefano V, Barbone F, Vitale M, Ferrante C, Bonanni L, Di Nicola M, Garzarella T, Marchionno LP, Malferrari G, Di Mascio R, Onofrj M, Franciotti R (2018) The predictive power of transcranial sonography in movement disorders: a longitudinal cohort study. Neurol Sci 39(11):1887–1894. https://doi.org/10.1007/s10072-018-3514-z
More JC, Nistico R, Dolman NP, Clarke VR, Alt AJ, Ogden AM, Buelens FP, Troop HM, Kelland EE, Pilato F, Bleakman D, Bortolotto ZA, Collingridge GL, Jane DE (2004) Characterisation of UBP296: a novel, potent and selective kainate receptor antagonist. Neuropharmacology 47(1):46–64. https://doi.org/10.1016/j.neuropharm.2004.03.005
Mori A (2020) How do adenosine A2A receptors regulate motor function? Parkinsonism Relat Disord 80(Suppl 1):S13–S20. https://doi.org/10.1016/j.parkreldis.2020.09.025
Mori A, Shindou T (2003) Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonists. Neurology 61(11 Suppl 6):S44–S48. https://doi.org/10.1212/01.wnl.0000095211.71092.a0. (Erratum in: Neurology. 2004 Jan 27;62(2):348)
Moskal N, Riccio V, Bashkurov M, Taddese R, Datti A, Lewis PN, McQuibban GA (2020) ROCK inhibitors upregulate the neuroprotective Parkin-mediated mitophagy pathway. Nat Commun 11:88
Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease (2003) The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord. 18(7):738–50. https://doi.org/10.1002/mds.10473
Mudò G, Mäkelä J, Di Liberto V, Tselykh TV, Olivieri M, Piepponen P, Eriksson O, Mälkiä A, Bonomo A, Kairisalo M et al (2012) Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson’s disease. Cell Mol Life Sci 69:1153–1165
Mullin S, Smith L, Lee K, D’Souza G, Woodgate P, Elflein J, Hällqvist J, Toffoli M, Streeter A, Hosking J et al (2020) Ambroxol for the Treatment of Patients with Parkinson Disease with and Without Glucocerebrosidase Gene Mutations: A Nonrandomized. Noncontrolled Trial JAMA Neurol 77:427–434
Nabavi SF, Sureda A, Dehpour AR, Shirooie S, Silva AS, Devi KP, Ahmed T, Ishaq N, Hashim R, Sobarzo-Sánchez E et al (2018) Regulation of autophagy by polyphenols: Paving the road for treatment of neurodegeneration. Biotechnol Adv 36:1768–1778
Newman-Tancredi A, Assié MB, Leduc N, Ormière AM, Danty N, Cosi C (2005) Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. Int J Neuropsychopharmacol 8(3):341–356. https://doi.org/10.1017/S1461145704005000
NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators. Pioglitazone in early Parkinson’s disease: A phase 2, multicentre, double-blind, randomised trial. Lancet Neurol. 2015, 14, 795–803
Normando EM, Davis BM, De Groef L, Nizari S, Turner LA, Ravindran N, Pahlitzsch M, Brenton J, Malaguarnera G, Guo L, Somavarapu S, Cordeiro MF (2016) The retina as an early biomarker of neurodegeneration in a rotenone-induced model of Parkinson’s disease: evidence for a neuroprotective effect of rosiglitazone in the eye and brain. Acta Neuropathol Commun 4(1):86. https://doi.org/10.1186/s40478-016-0346-z
Nuytemans K, Theuns J, Cruts M, van Broeckhoven C (2010) Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: A mutation update. Hum Mutat 31:763–780
Ohno Y (2011) Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson’s disease. CNS Neurosci Ther 17:58–65
Ohno Y, Shimizu S, Tokudome K, Kunisawa N, Sasa M (2015) New insight into the therapeutic role of the serotonergic system in Parkinson’s disease. Prog Neurobiol 134:104–121. https://doi.org/10.1016/j.pneurobio.2015.09.005
Okun MS (2014) Deep-brain stimulation–entering the era of human neural-network modulation. N Engl J Med 371(15):1369–1373. https://doi.org/10.1056/NEJMp1408779
Olanow CW, Brundin P (2013) Parkinson’s disease and alpha synuclein: Is Parkinson’s disease a prion-like disorder? Mov Disord 28:31–40
Olszewska DA, Fearon C, Lynch T (2016) Novel gene (TMEM230) linked to Parkinson’s disease. J Clin Mov Disord 3:17
O’Neill MJ, Murray TK, Whalley K, Ward MA, Hicks CA, Woodhouse S, Osborne DJ, Skolnick P (2004) Neurotrophic actions of the novel AMPA receptor potentiator, LY404187, in rodent models of Parkinson’s disease. Eur J Pharmacol 486(2):163–174. https://doi.org/10.1016/j.ejphar.2003.12.023
Opara J, Małecki A, Małecka E, Socha T (2017) Motor assessment in Parkinson`s disease. Ann Agric Environ Med 24(3):411–415. https://doi.org/10.5604/12321966.1232774
Oravivattanakul S, Benchaya L, Wu G, Ahmed A, Itin I, Cooper S, Gostkowski M, Rudolph J, Appleby K, Sweeney P, Fernandez HH (2015) Dopamine Transporter (DaT) Scan Utilization in a Movement Disorder Center. Mov Disord Clin Pract 3(1):31–35. https://doi.org/10.1002/mdc3.12261
Ozdilek B, Demircan B (2020) Serum microRNA expression levels in Turkish patients with Parkinson's disease. Int J Neurosci 1–9. https://doi.org/10.1080/00207454.2020.1784165
Pagan FL, Hebron ML, Wilmarth B, Torres-Yaghi Y, Lawler A, Mundel EE, Yusuf N, Starr NJ, Anjum M, Arellano J, Howard HH, Shi W, Mulki S, Kurd-Misto T, Matar S, Liu X, Ahn J, Moussa C (2020a) Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease: A Phase 2 Randomized Clinical Trial. JAMA Neurol 77(3):309–317. https://doi.org/10.1001/jamaneurol.2019.4200
Pagan FL, Wilmarth B, Torres-Yaghi Y, Hebron ML, Mulki S, Ferrante D, Matar S, Ahn J, Moussa C (2020b) Long-Term Safety and Clinical Effects of Nilotinib in Parkinson's Disease. Mov Disord. https://doi.org/10.1002/mds.28389
Pagano G, Niccolini F, Politis M (2016) Imaging in Parkinson’s disease. Clin Med (Lond) 16(4):371–375
Park HW, Park CG, Park M, Lee SH, Park HR, Lim J, Paek SH, Choy YB (2020) Intrastriatal administration of coenzyme Q10 enhances neuroprotection in a Parkinson’s disease rat model. Sci Rep 10(1):9572. https://doi.org/10.1038/s41598-020-66493-w
Parkinson Study Group STEADY-PD III Investigators (2020) Isradipine Versus Placebo in Early Parkinson Disease. Ann Intern Med 172:591–598
Parnetti L, Gaetani L, Eusebi P, Paciotti S, Hansson O, El-Agnaf O, Mollenhauer B, Blennow K, Calabresi P (2019) CSF and blood biomarkers for Parkinson’s disease. Lancet Neurol 18(6):573–586. https://doi.org/10.1016/S1474-4422(19)30024-9
Paton DM (2020) Istradefylline: adenosine A2A receptor antagonist to reduce “OFF” time in Parkinson’s disease. Drugs Today (Barc) 56(2):125–134. https://doi.org/10.1358/dot.2020.56.2.3098156
Patricio F, Morales-Andrade AA, Patricio-Martínez A, Limón ID (2020) Cannabidiol as a Therapeutic Target: Evidence of its Neuroprotective and Neuromodulatory Function in Parkinson’s Disease. Front Pharmacol. 11:595635. https://doi.org/10.3389/fphar.2020.595635
Pellecchia MT, Santangelo G, Picillo M, Pivonello R, Longo K, Pivonello C, Vitale C, Amboni M, De Rosa A, Moccia M, Erro R, De Michele G, Santoro L, Colao A, Barone P (2013) Serum epidermal growth factor predicts cognitive functions in early, drug-naive Parkinson’s disease patients. J Neurol 260(2):438–444. https://doi.org/10.1007/s00415-012-6648-6
Perry T, Lahiri DK, Chen D, Zhou J, Shaw KTY, Egan JM, Greig NH (2002) A Novel Neurotrophic Property of Glucagon-Like Peptide 1: A Promoter of Nerve Growth Factor-Mediated Differentiation in PC12 Cells. J Pharmacol Exp Ther 300:958–966
Phillips MCL, Murtagh DKJ, Gilbertson LJ, Asztely FJS, Lynch CDP (2018) Low-fat versus ketogenic diet in Parkinson’s disease: A pilot randomized controlled trial. Mov Disord. 33(8):1306–1314. https://doi.org/10.1002/mds.27390. (Erratum in: Mov Disord. 2019 Jan;34(1):157)
Piccinin E, Sardanelli A, Seibel P, Moschetta A, Cocco T, Villani G (2021) PGC-1s in the Spotlight with Parkinson’s Disease. Int J Mol Sci 22:3487
Pilleri M, Antonini A (2015) Therapeutic strategies to prevent and manage dyskinesias in Parkinson’s disease. Expert Opin Drug Saf 14(2):281–294. https://doi.org/10.1517/14740338.2015.988137
Pinna A, Serra M, Morelli M, Simola N (2018) Role of adenosine A2A receptors in motor control: relevance to Parkinson’s disease and dyskinesia. J Neural Transm (Vienna) 125(8):1273–1286. https://doi.org/10.1007/s00702-018-1848-6
Pisanò CA, Brugnoli A, Novello S, Caccia C, Keywood C, Melloni E, Vailati S, Padoani G, Morari M (2020) Safinamide inhibits in vivo glutamate release in a rat model of Parkinson’s disease. Neuropharmacology. 167:108006. https://doi.org/10.1016/j.neuropharm.2020.108006
Price DL, Koike MA, Khan A, Wrasidlo W, Rockenstein E, Masliah E, Bonhaus D (2018) The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson’s disease. Sci Rep 8:16165
Pyatigorskaya N, Gallea C, Garcia-Lorenzo D, Vidailhet M, Lehericy S (2014) A review of the use of magnetic resonance imaging in Parkinson’s disease. Ther Adv Neurol Disord 7(4):206–220. https://doi.org/10.1177/1756285613511507
Pytka K, Podkowa K, Rapacz A, Podkowa A, Żmudzka E, Olczyk A, Sapa J, Filipek B (2016) The role of serotonergic, adrenergic and dopaminergic receptors in antidepressant-like effect. Pharmacol Rep 68(2):263–274. https://doi.org/10.1016/j.pharep.2015.08.007
Qiao CM, Sun MF, Jia XB, Shi Y, Zhang BP, Zhou ZL, Zhao LP, Cui C, Shen YQ (2020) Sodium butyrate causes α-synuclein degradation by an Atg5-dependent and PI3K/Akt/mTOR-related autophagy pathway. Exp Cell Res. 387(1):111772. https://doi.org/10.1016/j.yexcr.2019.111772
Ramalingam M, Huh Y-J, Lee Y-I (2019) The Impairments of α-Synuclein and Mechanistic Target of Rapamycin in Rotenone-Induced SH-SY5Y Cells and Mice Model of Parkinson’s Disease. Front Neurosci 13:1028
Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med 342(20):1484–1491. https://doi.org/10.1056/NEJM200005183422004
Rascol O, Bronzova J, Hauser RA, Lang AE, Sampaio C, Theeuwes A, van de Witte SV (2012) Pardoprunox as adjunct therapy to levodopa in patients with Parkinson’s disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial. Parkinsonism Relat Disord 18(4):370–376. https://doi.org/10.1016/j.parkreldis.2011.12.006
Rawji V, Rocchi L, Foltynie T, Rothwell JC, Jahanshahi M (2020) Ropinirole, a dopamine agonist with high D3 affinity, reduces proactive inhibition: A double-blind, placebo-controlled study in healthy adults. Neuropharmacology 179:108278. https://doi.org/10.1016/j.neuropharm.2020.108278
Ren Y, Li H, Xie W, Wei N, Liu M (2019) MicroRNA-195 triggers neuroinflammation in Parkinson’s disease in a Rho-associated kinase 1-dependent manner. Mol Med Rep 19(6):5153–5161. https://doi.org/10.3892/mmr.2019.10176
Rizek P, Kumar N, Jog MS (2016) An update on the diagnosis and treatment of Parkinson disease. CMAJ 188(16):1157–1165
Robak LA, Jansen IE, Van Rooij J, Uitterlinden AG, Kraaij R, Jankovic J, Heutink P, Shulman JM, Nalls MA, Plagnol V et al (2017) Excessive burden of lysosomal storage disorder gene variants in Parkinson’s disease. Brain 140:3191–3203
Rocca WA (2018) The burden of Parkinson’s disease: a worldwide perspective. Lancet Neurol 17(11):928–929. https://doi.org/10.1016/S1474-4422(18)30355-7
Rocha EM, Smith GA, Park E, Cao H, Brown E, Hallett P, Isacson O (2015) Progressive decline of glucocerebrosidase in aging and Parkinson’s disease. Ann Clin Transl Neurol. 2(4):433–8. https://doi.org/10.1002/acn3.177
Rosengarten H, Bartoszyk GD, Quartermain D, Lin Y (2006) The effect of chronic administration of sarizotan, 5-HT1A agonist/D3/D4 ligand, on haloperidol-induced repetitive jaw movements in rat model of tardive dyskinesia. Prog Neuropsychopharmacol Biol Psychiatry 30(2):273–279. https://doi.org/10.1016/j.pnpbp.2005.08.014
Roser A-E, Tönges L, Lingor P (2017) Modulation of Microglial Activity by Rho-Kinase (ROCK) Inhibition as Therapeutic Strategy in Parkinson’s Disease and Amyotrophic Lateral Sclerosis. Front Aging Neurosci 9:94
Rossi ME, Ruottinen H, Saunamäki T, Elovaara I, Dastidar P (2014) Imaging brain iron and diffusion patterns: a follow-up study of Parkinson’s disease in the initial stages. Acad Radiol 21(1):64–71. https://doi.org/10.1016/j.acra.2013.09.018
Rott R, Szargel R, Shani V, Bisharat S, Engelender S (2014) α-Synuclein ubiquitination and novel therapeutic targets for Parkinson’s disease. CNS Neurol Disord Drug Targets 13(4):630–637. https://doi.org/10.2174/18715273113126660195
Roy A, Pahan K (2011) Prospects of Statins in Parkinson Disease. Neuroscientist 17:244–255
Sadeghian M, Marinova-Mutafchieva L, Broom L, Davis J, Virley D, Medhurst A, Dexter D (2012) Full and partial peroxisome proliferation-activated receptor-gamma agonists, but not delta agonist, rescue of dopaminergic neurons in the 6-OHDA Parkinsonian model is associated with inhibition of microglial activation and MMP expression. J Neuroimmunol 246:69–77
Saeed U, Compagnone J, Aviv RI, Strafella AP, Black SE, Lang AE, Masellis M (2017) Imaging biomarkers in Parkinson’s disease and Parkinsonian syndromes: current and emerging concepts. Transl Neurodegener 6:8
Safar MM, Abdelkader NF, Ramadan E, Kortam MA, Mohamed AF (2021) Novel mechanistic insights towards the repositioning of alogliptin in Parkinson’s disease. Life Sci. 287:120132. https://doi.org/10.1016/j.lfs.2021.120132
Salcedo I, Tweedie D, Li Y, Greig NH (2012) Neuroprotective and neurotrophic actions of glucagon-like peptide-1: An emerging opportunity to treat neurodegenerative and cerebrovascular disorders. J Cereb Blood Flow Metab 166:1586–1599
Saliminejad K, Khorram Khorshid HR, Soleymani Fard S, Ghaffari SH (2019) An overview of microRNAs: Biology, functions, therapeutics, and analysis methods. J Cell Physiol 234(5):5451–5465. https://doi.org/10.1002/jcp.27486
Samii A, Nutt JG, Ransom BR (2004) Parkinson’s disease. Lancet 363(9423):1783–1793. https://doi.org/10.1016/S0140-6736(04)16305-8
Samotus O, Parrent A, Jog M (2018) Spinal Cord Stimulation Therapy for Gait Dysfunction in Advanced Parkinson’s Disease Patients. Mov Disord 33(5):783–792. https://doi.org/10.1002/mds.27299
Sandor C, Honti F, Haerty W, Szewczyk-Krolikowski K, Tomlinson P, Evetts S, Millin S, Keane T, McCarthy SA, Durbin R et al (2017) Whole-exome sequencing of 228 patients with sporadic Parkinson’s disease. Sci Rep 7:41188
Sandoval DA, D’Alessio DA (2015) Physiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease. Physiol Rev 95:513–548
Sapru MK, Yates JW, Hogan S, Jiang L, Halter J, Bohn MC (2006) Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi. Exp Neurol 198(2):382–390. https://doi.org/10.1016/j.expneurol.2005.12.024
Sardi SP, Cedarbaum JM, Brundin P (2018) Targeted Therapies for Parkinson’s Disease: From Genetics to the Clinic. Mov Disord 33:684–696
Sarkar S, Floto RA, Berger Z, Imarisio S, Cordenier A, Pasco M, Cook LJ, Rubinsztein DC (2005) Lithium induces autophagy by inhibiting inositol monophosphatase. J Cell Biol 170:1101–1111
Sarkar S, Davies JE, Huang Z, Tunnacliffe A, Rubinsztein DC (2007) Trehalose, a Novel mTOR-Independent Autophagy Enhancer, Accelerates the Clearance of Mutant Huntingtin and α-Synuclein. J Biol Chem 282:5641–5652
Satue M, Obis J, Rodrigo MJ, Otin S, Fuertes MI, Vilades E, Gracia H, Ara JR, Alarcia R, Polo V, Larrosa JM, Pablo LE, Garcia-Martin E (2016) Optical Coherence Tomography as a Biomarker for Diagnosis, Progression, and Prognosis of Neurodegenerative Diseases. J Ophthalmol. 2016:8503859. https://doi.org/10.1155/2016/8503859
Scanzano A, Cosentino M (2015) Adrenergic regulation of innate immunity: A review. Front Pharmacol 6:171
Schapira AH (2004) Disease modification in Parkinson’s disease. Lancet Neurol 3(6):362–368. https://doi.org/10.1016/S1474-4422(04)00769-0
Schapira AH, Olanow CW (2004) Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA 291(3):358–364. https://doi.org/10.1001/jama.291.3.358
Schapira AH, Bezard E, Brotchie J, Calon F, Collingridge GL, Ferger B, Hengerer B, Hirsch E, Jenner P, Le Novère N, Obeso JA, Schwarzschild MA, Spampinato U, Davidai G (2006) Novel pharmacological targets for the treatment of Parkinson’s disease. Nat Rev Drug Discov 5(10):845–854. https://doi.org/10.1038/nrd2087
Scheffold A, Holtman IR, Dieni S, Brouwer N, Katz SF, Jebaraj BM, Kahle PJ, Hengerer B, Lechel A, Stilgenbauer S et al (2016) Telomere shortening leads to an acceleration of synucleinopathy and impaired microglia response in a genetic mouse model. Acta Neuropathol Commun 4:87
Schenk DB, Koller M, Ness DK, Griffith SG, Grundman M, Zago W, Soto J, Atiee G, Ostrowitzki S, Kinney GG (2017) First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers. Mov Disord. 32(2):211–218. https://doi.org/10.1002/mds.26878
Schmidt MF, Gan ZY, Komander D, Dewson G (2021) Ubiquitin signalling in neurodegeneration: mechanisms and therapeutic opportunities. Cell Death Differ 28(2):570–590. https://doi.org/10.1038/s41418-020-00706-7
Schultz JL, Brinker AN, Xu J, Ernst SE, Tayyari F, Rauckhorst AJ, Liu L, Uc EY, Taylor EB, Simmering JE, Magnotta VA, Welsh MJ, Narayanan NS (2022) A pilot to assess target engagement of terazosin in Parkinson’s disease. Parkinsonism Relat Disord. 94:79–83. https://doi.org/10.1016/j.parkreldis.2021.11.022
Schulz J, Pagano G, Fernández Bonfante JA, Wilson H, Politis M (2018) Nucleus basalis of Meynert degeneration precedes and predicts cognitive impairment in Parkinson’s disease. Brain 141(5):1501–1516. https://doi.org/10.1093/brain/awy072
Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, Shoulson I, Ascherio A, Parkinson Study Group PRECEPT Investigators, Hyson C, Gorbold E, Rudolph A, Kieburtz K, Fahn S, Gauger L, Goetz C, Seibyl J, Forrest M, Ondrasik J (2008) Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol 65(6):716–23. https://doi.org/10.1001/archneur.2008.65.6.nct70003
Schweitzer JS, Song B, Herrington TM, Park TY, Lee N, Ko S, Jeon J, Cha Y, Kim K, Li Q, Henchcliffe C, Kaplitt M, Neff C, Rapalino O, Seo H, Lee IH, Kim J, Kim T, Petsko GA, Ritz J, Cohen BM, Kong SW, Leblanc P, Carter BS, Kim KS (2020) Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinson’s Disease. N Engl J Med 382(20):1926–1932. https://doi.org/10.1056/NEJMoa1915872
Seifert KD, Wiener JI (2013) The impact of DaTscan on the diagnosis and management of movement disorders: A retrospective study. Am J Neurodegener Dis 2(1):29–34
Sharifi H, Mohajjel Nayebia A, Farajnia S (2012) The effect of chronic administration of buspirone on 6-hydroxydopamine-induced catalepsy in rats. Adv Pharm Bull. 2(1):127–31. https://doi.org/10.5681/apb.2012.019
Sharifi H, Mohajjel Nayebi A, Farajnia S, Haddadi R (2015) Effect of Buspirone, Fluoxetine and 8-OH-DPAT on Striatal Expression of Bax, Caspase-3 and Bcl-2 Proteins in 6-Hydroxydopamine-Induced Hemi-Parkinsonian Rats. Adv Pharm Bull. 5(4):491–5. https://doi.org/10.15171/apb.2015.067
Sharma N, Nehru B (2017) Curcumin affords neuroprotection and inhibits α-synuclein aggregation in lipopolysaccharide-induced Parkinson’s disease model. Inflammopharmacology 26:349–360
Shen L, Ji HF (2013) Low uric acid levels in patients with Parkinson’s disease: evidence from meta-analysis. BMJ Open. 3(11):e003620. https://doi.org/10.1136/bmjopen-2013-003620
Shi M, Zabetian CP, Hancock AM, Ginghina C, Hong Z, Yearout D, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Leverenz JB, Zhang J (2010) Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson’s disease. Neurosci Lett. 480(1):78–82. https://doi.org/10.1016/j.neulet.2010.06.009
Shukla R, Rajani M, Srivastava N, Barthwal MK, Dikshit M (2006) Nitrite and malondialdehyde content in cerebrospinal fluid of patients with Parkinson’s disease. Int J Neurosci 116(12):1391–1402. https://doi.org/10.1080/00207450500513989
Shvadchak VV, Afitska K, Yushchenko DA (2018) Inhibition of α-Synuclein Amyloid Fibril Elongation by Blocking Fibril Ends. Angew Chem Int Ed Engl 57(20):5690–5694. https://doi.org/10.1002/anie.201801071
Sian-Hülsmann J, Mandel S, Youdim MB, Riederer P (2011) The relevance of iron in the pathogenesis of Parkinson’s disease. J Neurochem 118(6):939–957. https://doi.org/10.1111/j.1471-4159.2010.07132.x
Simon DK, Simuni T, Elm J, Clark-Matott J, Graebner AK, Baker L, Dunlop SR, Emborg M, Kamp C, Morgan JC, Ross GW, Sharma S, Ravina B, NINDS NET-PD Investigators (2015) Peripheral Biomarkers of Parkinson’s Disease Progression and Pioglitazone Effects. J Parkinsons Dis 5(4):731–6. https://doi.org/10.3233/JPD-150666
Simuni T, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, Jennings D, Tanner CM, Trojanowski JQ, Shaw LM, Seibyl J, Schuff N, Singleton A, Kieburtz K, Toga AW, Mollenhauer B, Galasko D, Chahine LM, Weintraub D, Foroud T, Tosun D, Poston K, Arnedo V, Frasier M, Sherer T, Chowdhury S, Marek K; Parkinson's Progression Marker Initiative* (2018) Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort. Mov Disord. 33(5):771–782. https://doi.org/10.1002/mds.27361
Simuni T, Fiske B, Merchant K, Coffey CS, Klingner E, Caspell-Garcia C, Lafontant DE, Matthews H, Wyse RK, Brundin P, Simon DK, Schwarzschild M, Weiner D, Adams J, Venuto C, Dawson TM, Baker L, Kostrzebski M, Ward T, Rafaloff G; Parkinson Study Group NILO-PD Investigators and Collaborators (2020) Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol e204725. https://doi.org/10.1001/jamaneurol.2020.4725
Skoloudík D, Jelínková M, Blahuta J, Cermák P, Soukup T, Bártová P, Langová K, Herzig R (2014) Transcranial sonography of the substantia nigra: digital image analysis. AJNR Am J Neuroradiol. 35(12):2273–8. https://doi.org/10.3174/ajnr.A4049
Somola N (2013) Dopaminergic treatments for Parkinson’s disease: Light and Shadows. In: Emerging drugs and targets for Parkinson’s disease, pp. 61–82. Eds A. Mattinez, C. Gil. Cambridge: RSC Publishing
Song J-X, Lu J-H, Liu L-F, Chen L-L, Durairajan SSK, Yue Z, Zhang H-Q, Li M (2013) HMGB1 is involved in autophagy inhibition caused by SNCA/α-synuclein overexpression. Autophagy 10:144–154
Song J-X, Sun Y-R, Peluso I, Zeng Y, Yu X, Lu J, Xu Z, Wang M-Z, Liu L-F, Huang Y-Y et al (2016) A novel curcumin analog binds to and activates TFEB in vitro and in vivo independent of MTOR inhibition. Autophagy 12:1372–1389
Stayte S, Laloli KJ, Rentsch P, Lowth A, Li KM, Pickford R, Vissel B (2020) The kainate receptor antagonist UBP310 but not single deletion of GluK1, GluK2, or GluK3 subunits, inhibits MPTP-induced degeneration in the mouse midbrain. Exp Neurol 323:113062. https://doi.org/10.1016/j.expneurol.2019.113062
Stefani A, Lozano AM, Peppe A, Stanzione P, Galati S, Tropepi D, Pierantozzi M, Brusa L, Scarnati E, Mazzone P (2007) Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson’s disease. Brain 130(Pt 6):1596–1607. https://doi.org/10.1093/brain/awl346
Stefani A, Pierantozzi M, Olivola E et al (2017) Homovanillic acid in CSF of mild stage Parkinson’s disease patients correlates with motor impairment. Neurochem Int 105:58–63. https://doi.org/10.1016/j.neuint.2017.01.007
St-Pierre J, Drori S, Uldry M, Silvaggi JM, Rhee J, Jager S, Handschin C, Zheng K, Lin J, Yang W et al (2006) Suppression of Reactive Oxygen Species and Neurodegeneration by the PGC-1 Transcriptional Coactivators. Cell 127:397–408
Strafella AP, Bohnen NI, Pavese N et al (2018) Imaging Markers of Progression in Parkinson’s Disease. Mov Disord Clin Pract 5(6):586–596
Su Y, Deng MF, Xiong W, Xie AJ, Guo J, Liang ZH, Hu B, Chen JG, Zhu X, Man HY, Lu Y, Liu D, Tang B, Zhu LQ (2019) MicroRNA-26a/Death-Associated Protein Kinase 1 Signaling Induces Synucleinopathy and Dopaminergic Neuron Degeneration in Parkinson’s Disease. Biol Psychiatry 85(9):769–781. https://doi.org/10.1016/j.biopsych.2018.12.008
Sun J, Li H, Jin Y, Yu J, Mao S, Su KP, Ling Z, Liu J (2021) Probiotic Clostridium butyricum ameliorated motor deficits in a mouse model of Parkinson’s disease via gut microbiota-GLP-1 pathway. Brain Behav Immun 91:703–715. https://doi.org/10.1016/j.bbi.2020.10.014
Svenningsson P, Rosenblad C, Af Edholm Arvidsson K, Wictorin K, Keywood C, Shankar B, Lowe DA, Björklund A, Widner H (2015) Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson’s disease: a dose-finding study. Brain 138(Pt 4):963–73. https://doi.org/10.1093/brain/awu409
Swanson CR, Berlyand Y, Xie SX, Alcalay RN, Chahine LM, Chen-Plotkin AS (2015) Plasma apolipoprotein A1 associates with age at onset and motor severity in early Parkinson’s disease patients. Mov Disord. 30(12):1648–56. https://doi.org/10.1002/mds.26290
Tao H, Liu Y, Hou Y (2020) miRNA 384 5p regulates the progression of Parkinson’s disease by targeting SIRT1 in mice and SH SY5Y cell. Int J Mol Med. 45(2):441–450. https://doi.org/10.3892/ijmm.2019.4426
Tard C, Demailly F, Delval A, Semah F, Defebvre L, Dujardin K, Moreau C (2015) Hypometabolism in Posterior and Temporal Areas of the Brain is Associated with Cognitive Decline in Parkinson’s Disease. J Parkinsons Dis 5(3):569–574. https://doi.org/10.3233/JPD-150583
Tatenhorst L, Tönges L, Saal K-A, Koch JC, Szeg”o M, Bähr M, Lingor P (2014) Rho Kinase Inhibition by Fasudil in the Striatal 6-Hydroxydopamine Lesion Mouse Model of Parkinson Disease. J. Neuropathol. Exp. Neurol. 73:770–779
Tatura R, Kraus T, Giese A, Arzberger T, Buchholz M, Höglinger G, Müller U (2016) Parkinson’s disease: SNCA-, PARK2-, and LRRK2- targeting microRNAs elevated in cingulate gyrus. Parkinsonism Relat Disord 33:115–121. https://doi.org/10.1016/j.parkreldis.2016.09.028
Thome AD, Harms AS, Volpicelli-Daley LA, Standaert DG (2016) microRNA-155 Regulates Alpha-Synuclein-Induced Inflammatory Responses in Models of Parkinson Disease. J Neurosci 36(8):2383–2390. https://doi.org/10.1523/JNEUROSCI.3900-15.2016
Tilve S, Difato F, Chieregatti E (2015) Cofilin 1 activation prevents the defects in axon elongation and guidance induced by extracellular alpha-synuclein. Sci Rep 5:16524
Tolosa E, Wenning G, Poewe W (2006) The diagnosis of Parkinson’s disease. Lancet Neurol 5(1):75–86. https://doi.org/10.1016/S1474-4422(05)70285-4
Tong Y, Yamaguchi H, Giaime E, Boyle S, Kopan R, Kelleher RJ, Shen J (2010) Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of -synuclein, and apoptotic cell death in aged mice. Proc Natl Acad Sci USA 107:9879–9884
Tyagi S, Gupta P, Saini AS, Kaushal C, Sharma S (2011) The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases. J Adv Pharm Technol Res 2:236–240
Ueda J, Uemura N, Sawamura M, Taguchi T, Ikuno M, Kaji S, Taruno Y, Matsuzawa S, Yamakado H, Takahashi R (2021) Perampanel Inhibits α-Synuclein Transmission in Parkinson’s Disease Models. Mov Disord 36(7):1554–1564. https://doi.org/10.1002/mds.28558
Uehara T, Choong C-J, Nakamori M, Hayakawa H, Nishiyama K, Kasahara Y, Baba K, Nagata T, Yokota T, Tsuda H et al (2019) Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting α-synuclein as a novel therapy for Parkinson’s disease. Sci Rep 9:7567
Ulusoy GK, Celik T, Kayir H, Gürsoy M, Isik AT, Uzbay TI (2011) Effects of pioglitazone and retinoic acid in a rotenone model of Parkinson’s disease. Brain Res Bull 85:380–384
Vecchia DD, Kanazawa LKS, Wendler E, Hocayen PAS, Vital MABF, Takahashi RN, Da Cunha C, Miyoshi E, Andreatini R (2020) Ketamine reversed short-term memory impairment and depressive-like behavior in animal model of Parkinson’s disease. Brain Res Bull. 168:63–73. https://doi.org/10.1016/j.brainresbull.2020.12.011
Vega RB, Huss JM, Kelly DP (2000) The Coactivator PGC-1 Cooperates with Peroxisome Proliferator-Activated Receptor α in Transcriptional Control of Nuclear Genes Encoding Mitochondrial Fatty Acid Oxidation Enzymes. Mol Cell Biol 20:1868–1876
Vernon AC, Zbarsky V, Datla KP, Croucher MJ, Dexter DT (2007) Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo. J Neurochem 103(3):1075–1091. https://doi.org/10.1111/j.1471-4159.2007.04860.x
Verstraeten A, Theuns J, van Broeckhoven C (2015) Progress in unraveling the genetic etiology of Parkinson disease in a genomic era. Trends Genet 31:140–149
Villar-Cheda B, Meijide AD, Joglar B, Perez AIR, Guerra MJ, Labandeira-Garcia JL (2012) Involvement of microglial RhoA/RhoKinase pathway activation in the dopaminergic neuron death. Role of angiotensin via angiotensin type 1 receptors. Neurobiol Dis. 47:268–279
Wakabayashi K, Tanji K, Odagiri S, Miki Y, Mori F, Takahashi H (2013) The Lewy body in Parkinson’s disease and related neurodegenerative disorders. Mol Neurobiol 47(2):495–508. https://doi.org/10.1007/s12035-012-8280-y
Wang L, Zhang Q, Li H, Zhang H (2012) SPECT Molecular Imaging in Parkinson’s Disease. Biomed Res Int 2012:412486
Wang H, Ye Y, Zhu Z, Mo L, Lin C, Wang Q, Wang H, Gong X, He X, Lu G, Lu F, Zhang S (2016) MiR-124 Regulates Apoptosis and Autophagy Process in MPTP Model of Parkinson’s Disease by Targeting to Bim. Brain Pathol 26(2):167–176. https://doi.org/10.1111/bpa.12267
Wang Y, Yang Z, Le W (2017) Tiny But Mighty: Promising Roles of MicroRNAs in the Diagnosis and Treatment of Parkinson’s Disease. Neurosci Bull. 33(5):543–551. https://doi.org/10.1007/s12264-017-0160-z
Wang M, Li L, Zhang X, Liu Y, Zhu R, Liu L, Fang Y, Gao Z, Gao D (2018) Magnetic resveratrol liposomes as a new theranostic platform for magnetic resonance imaging guided Parkinson’s disease targeting therapy. ACS Sustain Chem Eng 6(12):17124–17133
Wang Z, Gao G, Duan C, Yang H (2019) Progress of immunotherapy of anti-α-synuclein in Parkinson’s disease. Biomed Pharmacother 115:108843. https://doi.org/10.1016/j.biopha.2019.108843
Wang X, Saegusa H, Huntula S, Tanabe T (2019b) Blockade of microglial Cav1.2 Ca2+ channel exacerbates the symptoms in a Parkinson’s disease model. Sci Rep 9:9138
Wang R, Li Q, He Y, Yang Y, Ma Q, Li C (2020b) miR-29c-3p inhibits microglial NLRP3 inflammasome activation by targeting NFAT5 in Parkinson’s disease. Genes Cells 25(6):364–374. https://doi.org/10.1111/gtc.12764
Wang Y, Bouabid S, Darvas M, Zhou FM (2020a) The antiparkinson drug ropinirole inhibits movement in a Parkinson's disease mouse model with residual dopamine neurons. Exp Neurol. 333:113427. https://doi.org/10.1016/j.expneurol.2020.113427
Weaver FM, Follett K, Stern M, Hur K, Harris C, Marks WJ Jr, Rothlind J, Sagher O, Reda D, Moy CS, Pahwa R, Burchiel K, Hogarth P, Lai EC, Duda JE, Holloway K, Samii A, Horn S, Bronstein J, Stoner G, Heemskerk J, Huang GD, CSP 468 Study Group (2009) Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA. 301(1):63–73. https://doi.org/10.1001/jama.2008.929
Weihofen A, Liu Y, Arndt JW, Huy C, Quan C, Smith BA, Baeriswyl JL, Cavegn N, Senn L, Su L, Marsh G, Auluck PK, Montrasio F, Nitsch RM, Hirst WD, Cedarbaum JM, Pepinsky RB, Grimm J, Weinreb PH (2019) Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson’s disease models. Neurobiol Dis 124:276–288. https://doi.org/10.1016/j.nbd.2018.10.016
Weingarten CP, Sundman MH, Hickey P, Chen NK (2015) Neuroimaging of Parkinson’s disease: Expanding views. Neurosci Biobehav Rev 59:16–52
Weiss D, Walach M, Meisner C, Fritz M, Scholten M, Breit S, Plewnia C, Bender B, Gharabaghi A, Wächter T, Krüger R (2013) Nigral stimulation for resistant axial motor impairment in Parkinson’s disease? A randomized controlled trial. Brain 136(Pt 7):2098–108. https://doi.org/10.1093/brain/awt122
Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, Lang AE, Rascol O, Ribeiro MJ, Remy P, Poewe WH, Hauser RA, Brooks DJ, REAL-PET Study Group (2003) Slower progression of Parkinson’s disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 54(1):93–101. https://doi.org/10.1002/ana.10609
Williams A, Gill S, Varma T, Jenkinson C, Quinn N, Mitchell R, Scott R, Ives N, Rick C, Daniels J, Patel S, Wheatley K, PD SURG Collaborative Group (2010) Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson’s disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol. 9(6):581–91. https://doi.org/10.1016/S1474-4422(10)70093-4
Wu RM, Chen RC, Chiueh CC (2000) Effect of MAO-B inhibitors on MPP+ toxicity in Vivo. Ann N Y Acad Sci 899:255–261. https://doi.org/10.1111/j.1749-6632.2000.tb06191.x
Wu J, Yu X, Xue K, Wu J, Wang R, Xie X, Li K, Yang Z, Yue J (2020) The Inhibition of miR-873 Provides Therapeutic Benefit in a Lipopolysaccharide-Induced Neuroinflammatory Model of Parkinson’s Disease. Oxid Med Cell Longev 15(2020):8735249. https://doi.org/10.1155/2020/8735249
Xie Y, Feng H, Peng S, Xiao J, Zhang J (2017) Association of plasma homocysteine, vitamin B12 and folate levels with cognitive function in Parkinson’s disease: A meta-analysis. Neurosci Lett 636:190–195
Xu K, Bastia E, Schwarzschild M (2005) Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson’s disease. Pharmacol Ther 105(3):267–310. https://doi.org/10.1016/j.pharmthera.2004.10.007
Xu Y, He Q, Wang M, Gao Y, Liu X, Li D, Xiong B, Wang W (2021) Safety and efficacy of magnetic resonance imaging-guided focused ultrasound neurosurgery for Parkinson’s disease: a systematic review. Neurosurg Rev 44(1):115–127. https://doi.org/10.1007/s10143-019-01216-y
Yang Z, Li T, Li S, Wei M, Qi H, Shen B, Chang RC, Le W, Piao F (2019a) Altered Expression Levels of MicroRNA-132 and Nurr1 in Peripheral Blood of Parkinson’s Disease: Potential Disease Biomarkers. ACS Chem Neurosci 10(5):2243–2249. https://doi.org/10.1021/acschemneuro.8b00460
Yang Z, Li T, Cui Y, Li S, Cheng C, Shen B, Le W (2019b) Elevated Plasma microRNA-105-5p Level in Patients With Idiopathic Parkinson’s Disease: A Potential Disease Biomarker. Front Neurosci 18(13):218. https://doi.org/10.3389/fnins.2019.00218
Yang X, Zhang M, Wei M, Wang A, Deng Y, Cao H (2020) MicroRNA-216a inhibits neuronal apoptosis in a cellular Parkinson’s disease model by targeting Bax. Metab Brain Dis 35(4):627–635. https://doi.org/10.1007/s11011-020-00546-x
Yang J, Luo S, Zhang J, Yu T, Fu Z, Zheng Y, Xu X, Liu C, Fan M, Zhang Z (2021) Exosome-mediated delivery of antisense oligonucleotides targeting α-synuclein ameliorates the pathology in a mouse model of Parkinson’s disease. Neurobiol Dis. 148:105218. https://doi.org/10.1016/j.nbd.2020.105218
Yao L, Ye Y, Mao H, Lu F, He X, Lu G, Zhang S (2018) MicroRNA-124 regulates the expression of MEKK3 in the inflammatory pathogenesis of Parkinson’s disease. J Neuroinflammation 15(1):13. https://doi.org/10.1186/s12974-018-1053-4
Ye Q, Huang W, Li D, Si E, Wang J, Wang Y, Chen C, Chen X (2016) Overexpression of PGC-1α Influences Mitochondrial Signal Transduction of Dopaminergic Neurons. Mol Neurobiol 53:3756–3770
Ygland Rödström E, Mattsson-Carlgren N, Janelidze S, Hansson O, Puschmann A (2022) Serum Neurofilament Light Chain as a Marker of Progression in Parkinson’s Disease: Long-Term Observation and Implications of Clinical Subtypes. J Parkinsons Dis 12(2):571–584. https://doi.org/10.3233/JPD-212866
Ylönen S, Siitonen A, Nalls MA, Ylikotila P, Autere J, Eerola-Rautio J, Gibbs R, Hiltunen M, Tienari PJ, Soininen H et al (2017) Genetic risk factors in Finnish patients with Parkinson’s disease. Park Relat Disord 45:39–43
Zago E, Dal Molin A, Dimitri GM, Xumerle L, Pirazzini C, Bacalini MG, Maturo MG, Azevedo T, Spasov S, Gómez-Garre P, Periñán MT, Jesús S, Baldelli L, Sambati L, Calandra-Buonaura G, Garagnani P, Provini F, Cortelli P, Mir P, Trenkwalder C, Mollenhauer B, Franceschi C, Liò P, Nardini C, PROPAG-AGEING Consortium (2022) Early downregulation of hsa-miR-144–3p in serum from drug-naïve Parkinson’s disease patients. Sci Rep. 12(1):1330. https://doi.org/10.1038/s41598-022-05227-6
Zaltieri M, Grigoletto J, Longhena F, Navarria L, Favero G, Castrezzati S, Colivicchi MA, Della Corte L, Rezzani R, Pizzi M, Benfenati F, Spillantini MG, Missale C, Spano P, Bellucci A (2015) α-synuclein and synapsin III cooperatively regulate synaptic function in dopamine neurons. J Cell Sci 128(13):2231–2243. https://doi.org/10.1242/jcs.157867
Zeng R, Luo DX, Li HP, Zhang QS, Lei SS, Chen JH (2019) MicroRNA-135b alleviates MPP+-mediated Parkinson’s disease in in vitro model through suppressing FoxO1-induced NLRP3 inflammasome and pyroptosis. J Clin Neurosci 65:125–133. https://doi.org/10.1016/j.jocn.2019.04.004
Zhang J, Mattison HA, Liu C, Ginghina C, Auinger P, McDermott MP, Stewart T, Kang UJ, Parkinson Study Group DATATOP Investigators, Cain KC, Shi M (2013) Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease. Acta Neuropathol. 126(5):671–82. https://doi.org/10.1007/s00401-013-1121-x
Zhang QJ, Du CX, Tan HH, Zhang L, Li LB, Zhang J, Niu XL, Liu J (2015a) Activation and blockade of serotonin7 receptors in the prelimbic cortex regulate depressive-like behaviors in a 6-hydroxydopamine-induced Parkinson’s disease rat model. Neuroscience 17(311):45–55. https://doi.org/10.1016/j.neuroscience.2015.10.016
Zhang Q, Pan Y, Yan R, Zeng B, Wang H, Zhang X, Li W, Wei H, Liu Z (2015b) Commensal bacteria direct selective cargo sorting to promote symbiosis. Nat Immunol 16:918–926
Zhang L-Q, Zhang W, Li T, Yang T, Yuan X, Zhou Y, Zou Q, Yang H, Gao F, Tian Y et al (2021a) GLP-1R activation ameliorated novel-object recognition memory dysfunction via regulating hippocampal AMPK/NF-κB pathway in neuropathic pain mice. Neurobiol Learn Mem 182:107463
Zhang JN, Huang YL, Yang HM, Wang Y, Gu L, Zhang H (2021b) Blockade of metabotropic glutamate receptor 5 attenuates axonal degeneration in 6-hydroxydopamine-induced model of Parkinson’s disease. Mol Cell Neurosci 110:103572. https://doi.org/10.1016/j.mcn.2020.103572
Zhang HQ, Wang JY, Li ZF, Cui L, Huang SS, Zhu LB, Sun Y, Yang R, Fan HH, Zhang X, Zhu JH (2021c) DNA Methyltransferase 1 Is Dysregulated in Parkinson’s Disease via Mediation of miR-17. Mol Neurobiol 58(6):2620–2633. https://doi.org/10.1007/s12035-021-02298-w
Zheng Y, Dong L, Liu N, Luo X, He Z (2020) Mir-141-3p Regulates Apoptosis and Mitochondrial Membrane Potential via Targeting Sirtuin1 in a 1-Methyl-4-Phenylpyridinium in vitro Model of Parkinson’s Disease. Biomed Res Int 6(2020):7239895. https://doi.org/10.1155/2020/7239895
Zhou J, Zhao Y, Li Z, Zhu M, Wang Z, Li Y, Xu T, Feng D, Zhang S, Tang F, Yao J (2020) miR-103a-3p regulates mitophagy in Parkinson’s disease through Parkin/Ambra1 signaling. Pharmacol Res 160:105197. https://doi.org/10.1016/j.phrs.2020.105197
Zhu Z, Yang C, Iyaswamy A, Krishnamoorthi S, Sreenivasmurthy SG, Liu J, Wang Z, Tong BC-K, Song J, Lu J et al (2019) Balancing mTOR Signaling and Autophagy in the Treatment of Parkinson’s Disease. Int J Mol Sci 20:728
Acknowledgements
The author (AM) would like to acknowledge the infrastructure and facility provided by the National Institute of Pharmaceutical Education and Research (NIPER), Guwahati and the Department of Pharmaceuticals, Ministry of Chemicals, and Fertilizers, Government of India.
Author information
Authors and Affiliations
Contributions
“Conceptualization, JA, AM and MAK; software, JA, AM and MAK; validation, JA, AM, NH, TS, RB, MMG, SA, MT and MAK.; formal analysis, NH, TS, RB, MMG, SA, MT.; investigation, NH, TS, RB, MMG, SA, MT; resources, MMG, SA, JA; writing original draft preparation, MAK, NH, RB, TS; writing, review and editing, JA, and AM; visualization, JA, MAK, NH, AM; supervision, JA, AM. All authors have read and agreed to the published version of the manuscript.”
Corresponding author
Ethics declarations
Ethics approval and consent to participate
This article does not contain any studies with human participants or animals performed by any of the authors.
Institutional review board
Not applicable.
Informed consent
Not applicable.
Consent for publication
All authors have given their consent for publication.
Conflict of interest
The authors declare no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Khan, M.A., Haider, N., Singh, T. et al. Promising biomarkers and therapeutic targets for the management of Parkinson's disease: recent advancements and contemporary research. Metab Brain Dis 38, 873–919 (2023). https://doi.org/10.1007/s11011-023-01180-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11011-023-01180-z